Biotech Showcase 2015 EBD Group Demy Colton Life Science Advisors Biotech Showcase 2015
Share:
Email this page Share this on LinkedIn Share this on Twitter

Biotech Showcase™ 2015 Presenting Companies

A list of presenters at Biotech Showcase™ 2015 will be published soon

Biotech Showcase 2014 presenting companies

Click on any row to see more company information

4P Therapeutics
4P Therapeutics
Norcross, Georgia, United States
4P Therapeutics is a private company developing novel transdermal drug delivery technologies and products. We develop transdermal products from technologies such as microneed...


Share this:Email this pageShare this on LinkedInShare this on Twitter

4P Therapeutics

4P Therapeutics
Track: A
City: Norcross
State: Georgia
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
4P Therapeutics is a private company developing novel transdermal drug delivery technologies and products. We develop transdermal products from technologies such as microneedles and skinporation with formulations of small and large molecules including biologics. We are considering partnerships and investments for our proprietary products in development.

Visit: http://www.4ptherapeutics.com

Biotech Showcase™ 2015
Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
(OTCQB:ATNM)
New York, New York, United States
Actinium is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy is...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.
Track: C
City: New York
State: New York
Country: United States
Ownership: PUBLIC
Ticker: ATNM
Stock exchange: OTCQB
Schedule information will be posted soon
Actinium is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with monoclonal antibodies. The Company develops other radiopharmaceuticals for select applications.

Visit: http://www.actiniumpharmaceuticals.com

Biotech Showcase™ 2015
Adaptimmune
Adaptimmune
Abingdon, United Kingdom
Adaptimmune has a unique platform technology in affinity-engineered T cell receptors (TCRs) in T cell therapy. With a TCR pipeline, convincing early stage clinical data in can...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Adaptimmune

Adaptimmune
Track: A
City: Abingdon
Country: United Kingdom
Ownership: PRIVATE
Schedule information will be posted soon
Adaptimmune has a unique platform technology in affinity-engineered T cell receptors (TCRs) in T cell therapy. With a TCR pipeline, convincing early stage clinical data in cancer and a route map to a commercial manufacturing process, its TCRs target the wide repertoire of internal cancer peptide antigens unavailable to antibody therapies.

Visit: http://www.adaptimmune.com

Biotech Showcase™ 2015
Admedus (formerly Allied Healthcare Group)
Admedus (formerly Allied Healthcare Group)
(ASX:AHZ)
Melbourne, Victoria, Australia
Admedus (ASX: AHZ) is a diversified healthcare company focused on developing next generation technologies with world class partners, acquiring strategic assets to grow its pro...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Admedus (formerly Allied Healthcare Group)

Admedus (formerly Allied Healthcare Group)
Track: D
City: Melbourne
State: Victoria
Country: Australia
Ownership: PUBLIC
Ticker: AHZ
Stock exchange: ASX
Schedule information will be posted soon
Admedus (ASX: AHZ) is a diversified healthcare company focused on developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical sales and distribution business. The Company has a portfolio of regenerative tissue programs and research in immunotherapies.

Visit: http://www.alliedhealthcaregroup.com.au

Biotech Showcase™ 2015
Advanced Cell Technology
Advanced Cell Technology
(OTCBB:ACTC)
Santa Monica, California, United States
Advanced Cell Technology (“ACT”; ACTC.OB), is a biotechnology company developing cellular therapies for treating diseases that impact millions of people worldwide. ACT is ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Advanced Cell Technology

Advanced Cell Technology
Track: C
City: Santa Monica
State: California
Country: United States
Ownership: PUBLIC
Ticker: ACTC
Stock exchange: OTCBB
Schedule information will be posted soon
Advanced Cell Technology (“ACT”; ACTC.OB), is a biotechnology company developing cellular therapies for treating diseases that impact millions of people worldwide. ACT is currently conducting the only human embryonic stem cell (hESC)-based clinical trials: three Phase I/II trials in the US and one in Europe. Interim results from the US trials indicate a very good safety profile, and that visual acuity for a majority of the patients improved over baseline measurements.

Visit: http://www.advancedcell.com

Biotech Showcase™ 2015
Advaxis, Inc.
Advaxis, Inc.
(NASDAQ:ADXS)
Princeton, New Jersey, United States
Advaxis is a clinical-stage biotechnology company developing the next generation of cancer immunotherapies. The company's lead product candidate, ADXS-HPV, is in Phase 1 and P...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Advaxis, Inc.

Advaxis, Inc.
Track: C
City: Princeton
State: New Jersey
Country: United States
Ownership: PUBLIC
Ticker: ADXS
Stock exchange: NASDAQ
Schedule information will be posted soon
Advaxis is a clinical-stage biotechnology company developing the next generation of cancer immunotherapies. The company's lead product candidate, ADXS-HPV, is in Phase 1 and Phase 2 development for HPV-associated cancers, including invasive cervical cancer, head and neck cancer, and anal cancer. Advaxis raised $26.5 million through its recent public offering. 

Visit: http://www.advaxis.com

Biotech Showcase™ 2015
Aethlon Medical Inc.
Aethlon Medical Inc.
(OTCBB:AEMD)
San Diego, California, United States
Aethlon Medical creates medical devices to address life-threatening diseases. The Aethlon Hemopurifier®, which addresses a broad-spectrum of viral pathogens and immunosuppres...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Aethlon Medical Inc.

Aethlon Medical Inc.
Track: C
City: San Diego
State: California
Country: United States
Ownership: PUBLIC
Ticker: AEMD
Stock exchange: OTCBB
Schedule information will be posted soon
Aethlon Medical creates medical devices to address life-threatening diseases. The Aethlon Hemopurifier®, which addresses a broad-spectrum of viral pathogens and immunosuppressive exosomes was recently approved for clinical trials by the FDA. Aethlon also operates under two Department of Defense contracts and maintains a diagnostic subsidiary known as Exosome Sciences, Inc.

Visit: http://www.aethlonmedical.com

Biotech Showcase™ 2015
AIMM Therapeutics BV
AIMM Therapeutics BV
Amsterdam, Netherlands
AIMM Therapeutics is a private clinical stage (phase II) antibody company with programs in oncology and infectious disease. AIMM immortalizes nearly the entire B cell repertoi...


Share this:Email this pageShare this on LinkedInShare this on Twitter

AIMM Therapeutics BV

AIMM Therapeutics BV
Track: A
City: Amsterdam
Country: Netherlands
Ownership: PRIVATE
Schedule information will be posted soon
AIMM Therapeutics is a private clinical stage (phase II) antibody company with programs in oncology and infectious disease. AIMM immortalizes nearly the entire B cell repertoire from human patients or vaccinated rabbits enabling the isolation and direct functional testing of extremely rare antibodies. AIMM is funded through four antibody partnerships.

Visit: http://www.aimmtherapeutics.com

Biotech Showcase™ 2015
ALK-Abello A/S
ALK-Abello A/S
(NASDAQ OMX:ALK B)
Horsholm, Denmark
ALK-Abello A/S is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is the world leader in allergy immunotherapy –...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ALK-Abello A/S

ALK-Abello A/S
Track: C
City: Horsholm
Country: Denmark
Ownership: PUBLIC
Ticker: ALK B
Stock exchange: NASDAQ OMX
Schedule information will be posted soon
ALK-Abello A/S is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is the world leader in allergy immunotherapy – a unique treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Merck and Torii to commercialise allergy immunotherapy tablets in North America and Japan, respectively. 

Visit: http://www.alk.com

Biotech Showcase™ 2015
AlloCure, Inc.
AlloCure, Inc.
Burlington, Massachusetts, United States
AlloCure is pioneering medicine for kidney health.  The company is developing AC607, a mesenchymal stem cell therapy for the treatment of acute kidney injury. AlloCure is con...


Share this:Email this pageShare this on LinkedInShare this on Twitter

AlloCure, Inc.

AlloCure, Inc.
Track: B
City: Burlington
State: Massachusetts
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
AlloCure is pioneering medicine for kidney health.  The company is developing AC607, a mesenchymal stem cell therapy for the treatment of acute kidney injury. AlloCure is conducting ACT-AKI, a phase 2 international, multi-center, double-blinded, placebo controlled 200 subject trial with results expected in 2014. 

Visit: http://www.allocure.com

Biotech Showcase™ 2015
Amarantus
Amarantus
(OTCQB:AMBS)
San Francisco, California, United States
Amarantus BioScience is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis. The Company has an exclusiv...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Amarantus

Amarantus
Track: D
City: San Francisco
State: California
Country: United States
Ownership: PUBLIC
Ticker: AMBS
Stock exchange: OTCQB
Schedule information will be posted soon
Amarantus BioScience is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test (“LymPro Test®”) for Alzheimer’s disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF")

Visit: http://www.amarantus.com

Biotech Showcase™ 2015
ANERGIS SA
ANERGIS SA
Epalinges, Switzerland
Anergis is a Swiss biopharmaceutical company developing proprietary COP allergy vaccines. Anergis vaccines require only 2 months of treatment to provide long lasting allergy d...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ANERGIS SA

ANERGIS SA
Track: A
City: Epalinges
Country: Switzerland
Ownership: PRIVATE
Schedule information will be posted soon
Anergis is a Swiss biopharmaceutical company developing proprietary COP allergy vaccines. Anergis vaccines require only 2 months of treatment to provide long lasting allergy desensitization. Anergis lead-product, AllerT for patients with allergy to birch pollen, successfully completed Phase IIb in 2013 and will enter Phase III shortly.

Visit: http://www.anergis.ch

Biotech Showcase™ 2015
Antisense Therapeutics Ltd
Antisense Therapeutics Ltd
(ASX:ANP)
Toorak, Victoria, Australia
Antisense Therapeutics Ltd (ASX:ANP) is an Australian biotech company developing its advanced-stage pipeline of novel second-generation antisense drugs.  Lead compounds are i...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Antisense Therapeutics Ltd

Antisense Therapeutics Ltd
Track: C
City: Toorak
State: Victoria
Country: Australia
Ownership: PUBLIC
Ticker: ANP
Stock exchange: ASX
Schedule information will be posted soon
Antisense Therapeutics Ltd (ASX:ANP) is an Australian biotech company developing its advanced-stage pipeline of novel second-generation antisense drugs.  Lead compounds are in Phase 2 clinical development with near-term milestones, acting on validated targets in acromegaly and multiple sclerosis.  Leveraging technology partnership/exclusive worldwide licensing agreement with antisense world leader, Isis Pharmaceuticals. 

Visit: http://www.antisense.com.au

Biotech Showcase™ 2015
Apogenix GmbH
Apogenix GmbH
Heidelberg, Germany
Apogenix develops protein therapeutics to treat life-threatening diseases such as, e.g., glioblastoma (GB). As shown in a controlled phase II trial in recurrent GB, the compan...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Apogenix GmbH

Apogenix GmbH
Track: A
City: Heidelberg
Country: Germany
Ownership: PRIVATE
Schedule information will be posted soon
Apogenix develops protein therapeutics to treat life-threatening diseases such as, e.g., glioblastoma (GB). As shown in a controlled phase II trial in recurrent GB, the company’s lead drug candidate APG101 prolongs overall survival while exhibiting an excellent safety profile. Apogenix is looking for partners to advance this compound to the market.

Visit: http://www.apogenix.com

Biotech Showcase™ 2015
Aradigm Corporation
Aradigm Corporation
(OTCBB:ARDM)
Hayward, California, United States
The Company signed a worldwide licensing deal with Grifols (Nasdaq: GRFS) that funds upcoming Phase III clinical trials with Pulmaquin® in bronchiectasis patients, and may pu...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Aradigm Corporation

Aradigm Corporation
Track: C
City: Hayward
State: California
Country: United States
Ownership: PUBLIC
Ticker: ARDM
Stock exchange: OTCBB
Schedule information will be posted soon
The Company signed a worldwide licensing deal with Grifols (Nasdaq: GRFS) that funds upcoming Phase III clinical trials with Pulmaquin® in bronchiectasis patients, and may pursue additional indications such as cystic fibrosis, non-TB mycobacterial lung infections, and biodefense applications. The first pivotal trials are expected to begin in H1-2014.

Visit: http://www.aradigm.com

Biotech Showcase™ 2015
Arbovax Inc
Arbovax Inc
Raleigh, North Carolina, United States
Arbovax is engaged in the development of vaccines for protection against mosquito-borne diseases that collectively infect over 300 million people annually. Mosquito-borne vir...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Arbovax Inc

Arbovax Inc
Track: A
City: Raleigh
State: North Carolina
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Arbovax is engaged in the development of vaccines for protection against mosquito-borne diseases that collectively infect over 300 million people annually. Mosquito-borne viruses provide some of the most important examples of emerging and resurging diseases of global significance including Dengue Fever, Japanese Encephalitis, West Nile and Yellow Fever; the market for an effective Dengue virus vaccine alone is in excess of $2.0 billion.

Visit: http://www.arbovax.com

Biotech Showcase™ 2015
ARCA biopharma
ARCA biopharma
(NASDAQ:ABIO)
Westminster, Colorado, United States
ARCA is developing targeted therapies for cardiovascular diseases. Its pivotal Phase 2B/3 trial of Gencaro in atrial fibrillation is expected to begin in Q1 2014. The trial ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ARCA biopharma

ARCA biopharma
Track: C
City: Westminster
State: Colorado
Country: United States
Ownership: PUBLIC
Ticker: ABIO
Stock exchange: NASDAQ
Schedule information will be posted soon
ARCA is developing targeted therapies for cardiovascular diseases. Its pivotal Phase 2B/3 trial of Gencaro in atrial fibrillation is expected to begin in Q1 2014. The trial is being conducted in collaboration with Medtronic, LabCorp and DCRI. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment.

Visit: http://www.arcabiopharma.com

Biotech Showcase™ 2015
Arch Therapeutics
Arch Therapeutics
(OTCBB:ARTH)
Wellesley, Massachusetts, United States
Arch Therapeutics is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking during surgery and trauma care based on our innovat...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Arch Therapeutics

Arch Therapeutics
Track: C
City: Wellesley
State: Massachusetts
Country: United States
Ownership: PUBLIC
Ticker: ARTH
Stock exchange: OTCBB
Schedule information will be posted soon
Arch Therapeutics is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking during surgery and trauma care based on our innovative self-assembling peptide technology platform. Arch’s flagship development stage product candidate, AC5TM, is being designed to achieve faster and safer hemostasis during surgical procedures.

Visit: http://www.archtherapeutics.com/

Biotech Showcase™ 2015
Arcturus Therapeutics
Arcturus Therapeutics
San Diego, California, United States
Arcturus is an RNA therapeutics company pursuing rare diseases using proprietary LUNAR© delivery technology.  The company has demonstrated superior potency, safety, and scal...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Arcturus Therapeutics

Arcturus Therapeutics
Track: A
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Arcturus is an RNA therapeutics company pursuing rare diseases using proprietary LUNAR© delivery technology.  The company has demonstrated superior potency, safety, and scalability of its platform.  Arcturus is funded by high net worth investors from U.S., Canada, and Japan; and looking to secure select partners to develop superior RNA therapeutics.

Visit: http://www.ArcturusRx.com

Biotech Showcase™ 2015
arGEN-X
arGEN-X
AH BREDA, Netherlands
arGEN-X specializes both in the discovery of human antibodies modulating complex disease target function and in the development of highly differentiated therapeutic product...


Share this:Email this pageShare this on LinkedInShare this on Twitter

arGEN-X

arGEN-X
Track: B
City: AH BREDA
Country: Netherlands
Ownership: PRIVATE
Schedule information will be posted soon
arGEN-X specializes both in the discovery of human antibodies modulating complex disease target function and in the development of highly differentiated therapeutic products in autoimmunity and cancer. arGEN-X has two programs in Phase Ib clinical trials, a pipeline of preclinical opportunities and partnered programs with Lilly and Shire.

Visit: http://www.argen-x.com

Biotech Showcase™ 2015
Arno Therapeutics, Inc.
Arno Therapeutics, Inc.
(OTCQB:ARNI)
Flemington, New Jersey, United States
Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Arno Therapeutics, Inc.

Arno Therapeutics, Inc.
Track: C
City: Flemington
State: New Jersey
Country: United States
Ownership: PUBLIC
Ticker: ARNI
Stock exchange: OTCQB
Schedule information will be posted soon
Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors.

Visit: http://www.arnothera.com/

Biotech Showcase™ 2015
Artery Therapeutics, Inc.
Artery Therapeutics, Inc.
San Ramon, California, United States
San Francisco based translational biotechnology company focusing on finding a cure for Diabetes, Alzheimer's Disease, Atherosclerosis and prevention of heart disease through t...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Artery Therapeutics, Inc.

Artery Therapeutics, Inc.
Track: A
City: San Ramon
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
San Francisco based translational biotechnology company focusing on finding a cure for Diabetes, Alzheimer's Disease, Atherosclerosis and prevention of heart disease through the ABCA1 transporter.

Visit: http://arterytx.com/

Biotech Showcase™ 2015
Asceneuron SA
Asceneuron SA
Lausanne, Switzerland
Asceneuron is a biopharmaceutical company poised to deliver breakthrough medicines by developing effective therapeutics for orphan tauopathies and improved symptomatic drugs f...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Asceneuron SA

Asceneuron SA
Track: A
City: Lausanne
Country: Switzerland
Ownership: PRIVATE
Schedule information will be posted soon
Asceneuron is a biopharmaceutical company poised to deliver breakthrough medicines by developing effective therapeutics for orphan tauopathies and improved symptomatic drugs for Alzheimer’s disease. Our first in class small molecule tau program targeting the O-GlcNAcase enzyme is rapidly progressing toward preclinical development with anticipated Phase I entry by mid-2015.

Visit: http://www.asceneuron.com

Biotech Showcase™ 2015
Assurex Health
Assurex Health
Mason, Ohio, United States
Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Healt...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Assurex Health

Assurex Health
Track: A
City: Mason
State: Ohio
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well as evidence-based medicine and clinical pharmacology.

Visit: http://assurexhealth.com/

Biotech Showcase™ 2015
Atossa Genetics, Inc.
Atossa Genetics, Inc.
(NASDAQ:ATOS)
Seattle, Washington, United States
Atossa Genetics, Inc. is focused on proprietary products and services related to breast health through the commercialization of medical devices and, through its wholly-owned s...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Atossa Genetics, Inc.

Atossa Genetics, Inc.
Track: C
City: Seattle
State: Washington
Country: United States
Ownership: PUBLIC
Ticker: ATOS
Stock exchange: NASDAQ
Schedule information will be posted soon
Atossa Genetics, Inc. is focused on proprietary products and services related to breast health through the commercialization of medical devices and, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc., the offering of laboratory services and tests.

Visit: http://www.atossagenetics.com

Biotech Showcase™ 2015
Avexxin AS
Avexxin AS
Trondheim, Norway
Avexxin AS is a clinical stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics for patients with chronic inflammatory con...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Avexxin AS

Avexxin AS
Track: A
City: Trondheim
Country: Norway
Ownership: PRIVATE
Schedule information will be posted soon
Avexxin AS is a clinical stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics for patients with chronic inflammatory conditions. Avexxin's advanced understanding of the biology of the inflammatory process has resulted in a novel therapeutic approach for the treatment of psoriasis and other inflammatory disorders.

Visit: http://www.avexxin.com

Biotech Showcase™ 2015
Avisa Pharma Inc
Avisa Pharma Inc
Albuquerque, New Mexico, United States
Drug/Device, First to Respiratory Market. Focus on Healthcare Acquired Pneumonia (HCAP). De-risked Model, New Use of an Existing Drug. Human POC, safety/dose response complete...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Avisa Pharma Inc

Avisa Pharma Inc
Track: A
City: Albuquerque
State: New Mexico
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Drug/Device, First to Respiratory Market. Focus on Healthcare Acquired Pneumonia (HCAP). De-risked Model, New Use of an Existing Drug. Human POC, safety/dose response completed. Billion $ plus Market Opportunity. Short Timeline to Exit. Capital Efficient. Growing IP. Bending the Healthcare Cost Curve.

Visit: http://www.avisapharma.com

Biotech Showcase™ 2015
BBU Pharmaceuticals
BBU Pharmaceuticals
Moscow, Russian Federation
BBU Pharmaceuticals develops a new generation Parkinson’s disease drug BDG-DOPAMINE® featuring a direct delivery of dopamine to the brain across the blood-brain barrier via...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BBU Pharmaceuticals

BBU Pharmaceuticals
Track: A
City: Moscow
Country: Russian Federation
Ownership: PRIVATE
Schedule information will be posted soon
BBU Pharmaceuticals develops a new generation Parkinson’s disease drug BDG-DOPAMINE® featuring a direct delivery of dopamine to the brain across the blood-brain barrier via a proprietary delivery technology. 2011BDG-DOPAMINE® offers a massive improvement over the existing drug substance (levodopa).

Visit: http://www.bdirectgold.com/

Biotech Showcase™ 2015
BENITEC BIOPHARMA
BENITEC BIOPHARMA
(ASX:BLT)
BALMAIN, New South Wales, Australia
Benitec is a clinical stage biotechnology company. Our lead compound, TT-034, a single shot cure for Hepatitis C, is moving into the clinic in two US based sites In addition t...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BENITEC BIOPHARMA

BENITEC BIOPHARMA
Track: C
City: BALMAIN
State: New South Wales
Country: Australia
Ownership: PUBLIC
Ticker: BLT
Stock exchange: ASX
Schedule information will be posted soon
Benitec is a clinical stage biotechnology company. Our lead compound, TT-034, a single shot cure for Hepatitis C, is moving into the clinic in two US based sites In addition the company has a pipeline of therapeutic programs based on its transformational gene-silencing technology, ddRNAi. Including hepatitis B, AMD, cancer-associated pain, drug resistant lung cancer and OPMD.

Visit: http://www.benitec.com/

Biotech Showcase™ 2015
Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc.
(OTCBB:BPTH)
Houston, Texas, United States
Bio-Path is focused on developing therapeutic products utilizing its proprietary liposomal delivery technology.   Its lead product, Liposomal Grb-2, is in a Phase I study fo...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc.
Track: A
City: Houston
State: Texas
Country: United States
Ownership: PUBLIC
Ticker: BPTH
Stock exchange: OTCBB
Schedule information will be posted soon
Bio-Path is focused on developing therapeutic products utilizing its proprietary liposomal delivery technology.   Its lead product, Liposomal Grb-2, is in a Phase I study for blood cancers and in preclinical studies for triple negative and inflammatory breast cancers.  Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.

Visit: http://www.biopathholdings.com

Biotech Showcase™ 2015
BioAtla
BioAtla
San Diego, California, United States
BioAtla is developing novel, uniquely enabled protein products to change the future of medicine and personalized health. These include conditionally activated monoclonal antib...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BioAtla

BioAtla
Track: A
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
BioAtla is developing novel, uniquely enabled protein products to change the future of medicine and personalized health. These include conditionally activated monoclonal antibodies addressing currently untreatable tumors. We leverage our capabilities through a long-term R&D arrangement with researchers at BioDuro, a PPD company in Asia.

Visit: http://www.bioatla.com

Biotech Showcase™ 2015
BioCrea
BioCrea
Radebeul, Germany
Patient-derived data drive BioCrea’s drug discovery in CNS diseases. We turn concepts into drug candidates. With programs in Depression, Epilepsy, Autism, Huntington’s dis...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BioCrea

BioCrea
Track: B
City: Radebeul
Country: Germany
Ownership: PRIVATE
Schedule information will be posted soon
Patient-derived data drive BioCrea’s drug discovery in CNS diseases. We turn concepts into drug candidates. With programs in Depression, Epilepsy, Autism, Huntington’s disease, Schizophrenia and Lou Gehrig’s disease, we have established a diverse preclinical portfolio of partnering opportunities. BioCrea’s technology is validated through past partnerships with Boehringer Ingelheim, Pfizer, Wyeth and GSK.

Visit: http://www.biocrea.com

Biotech Showcase™ 2015
BioInspire Technologies
Palo Alto, California, United States
BioInspire Technologies is a medical technology company intending to transform the care of patients by providing physicians with highly adherent, bioabsorbable film which can ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BioInspire Technologies

Track: B
City: Palo Alto
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
BioInspire Technologies is a medical technology company intending to transform the care of patients by providing physicians with highly adherent, bioabsorbable film which can “stick” to any tissue to provide a protective barrier and/or deliver drugs locally to the target site. Company’s first product, the SinuBand™ Bioabsorbable Dressing, contains an embedded steroid designed to aid in the post-operative care of nasal surgery patients. The technology can be adopted for a variety of indications

Visit: http://bioinspiretechnologies.com/

Biotech Showcase™ 2015
BioKier
BioKier
Chapel Hill, North Carolina, United States
BioKier is developing an oral small-molecule therapeutic for the treatment of type 2 diabetes. It is designed to mimic effect on diabetes of bariatric weight-loss surgery, wh...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BioKier

BioKier
Track: A
City: Chapel Hill
State: North Carolina
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
BioKier is developing an oral small-molecule therapeutic for the treatment of type 2 diabetes. It is designed to mimic effect on diabetes of bariatric weight-loss surgery, which is effective in improving or resolving diabetes. Current investors include Broadview Ventures and the American Heart Association Science and Technology Accelerator Program.

Visit: http://www.biokier.com

Biotech Showcase™ 2015
BioLineRx
BioLineRx
(NASDAQ:BLRX)
Jerusalem, Israel
BioLineRx is a publicly-traded biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs, as well as those with advantages ov...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BioLineRx

BioLineRx
Track: D
City: Jerusalem
Country: Israel
Ownership: PUBLIC
Ticker: BLRX
Stock exchange: NASDAQ
Schedule information will be posted soon
BioLineRx is a publicly-traded biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs, as well as those with advantages over currently available therapies. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

Visit: http://www.biolinerx.com

Biotech Showcase™ 2015
Biomatrica
Biomatrica
San Diego, California, United States
Biomatrica has numerous innovations for preservation of biological materials, enhancement of assays, and elimination of freezing in cell-based therapeutics. Our platform provi...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Biomatrica

Biomatrica
Track: A
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Biomatrica has numerous innovations for preservation of biological materials, enhancement of assays, and elimination of freezing in cell-based therapeutics. Our platform provides room temperature stabilization of DNA, RNA, proteins, cells and assays. We are seeking financing to accelerate commercial development and conduct new research in whole cell therapeutics.

Visit: http://www.biomatrica.com

Biotech Showcase™ 2015
Biomay AG
Biomay AG
Vienna, Austria
Biomay is a global leader in the discovery and development of innovative immunotherapeutics for allergies, which offer a paradigm change in the way allergies are treated today...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Biomay AG

Biomay AG
Track: A
City: Vienna
Country: Austria
Ownership: PRIVATE
Schedule information will be posted soon
Biomay is a global leader in the discovery and development of innovative immunotherapeutics for allergies, which offer a paradigm change in the way allergies are treated today. Our products are based on a proprietary technology platform which allows tayloring vaccines to any allergen. Our lead product BM32 for grass pollen allergies is in a phase IIb clinical Trial with readout in Q4/2014

Visit: http://www.biomay.com

Biotech Showcase™ 2015
Bionomics
Bionomics
(ASX:BNO)
Thebarton, South Australia, Australia
Bionomics is a biopharmaceutical company focused on discovering and developing new treatments for cancer and serious disorders of the central nervous system. The company has a...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Bionomics

Bionomics
Track: C
City: Thebarton
State: South Australia
Country: Australia
Ownership: PUBLIC
Ticker: BNO
Stock exchange: ASX
Schedule information will be posted soon
Bionomics is a biopharmaceutical company focused on discovering and developing new treatments for cancer and serious disorders of the central nervous system. The company has a strong out-license record in conjunction with its in-house development program which has seen highly promising drug candidates enter clinical trials.

Visit: http://www.bionomics.com.au

Biotech Showcase™ 2015
Bionor Pharma
Bionor Pharma
(OSE:BIONOR)
Oslo, Norway
Bionor Pharma is a biotechnology company focusing on the treatment of life threatening viral diseases, especially HIV and has a platform capability of addressing other key v...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Bionor Pharma

Bionor Pharma
Track: C
City: Oslo
Country: Norway
Ownership: PUBLIC
Ticker: BIONOR
Stock exchange: OSE
Schedule information will be posted soon
Bionor Pharma is a biotechnology company focusing on the treatment of life threatening viral diseases, especially HIV and has a platform capability of addressing other key viral diseases including Influenza, HPV, Herpes and Hepatitis C. The Company’s lead investigational product is Vacc-4x, one of the furthest advanced cellular therapeutic vaccines in the HIV space. Vacc-4x is currently in several exploratory Phase II trials with data expected in 2014.

Visit: http://www.bionorpharma.com

Biotech Showcase™ 2015
Biotron Limited
Biotron Limited
(ASX:BIT)
North Ryde, New South Wales, Australia
Biotron is a mid-stage drug development company with clinical programs targeting Hepatitis C and HIV. BIT225 is a first-in-class drug that has shown good efficacy against HCV....


Share this:Email this pageShare this on LinkedInShare this on Twitter

Biotron Limited

Biotron Limited
Track: C
City: North Ryde
State: New South Wales
Country: Australia
Ownership: PUBLIC
Ticker: BIT
Stock exchange: ASX
Schedule information will be posted soon
Biotron is a mid-stage drug development company with clinical programs targeting Hepatitis C and HIV. BIT225 is a first-in-class drug that has shown good efficacy against HCV. There is also strong potential for BIT225 in its ability to attack HIV viral reservoirs, with potential to contribute to eradication of HIV.

Visit: http://www.biotron.com.au

Biotech Showcase™ 2015
Blend Therapeutics
Blend Therapeutics
Watertown, Massachusetts, United States
Blend Therapeutics is advancing highly targeted, effective, oncology therapies, including novel platinums and a breakthrough modular targeted drug delivery platform. These are...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Blend Therapeutics

Blend Therapeutics
Track: B
City: Watertown
State: Massachusetts
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Blend Therapeutics is advancing highly targeted, effective, oncology therapies, including novel platinums and a breakthrough modular targeted drug delivery platform. These are based on its drug discovery engine and patented nanotechnology. Blend was founded on technology developed at MIT/Harvard and has top-tier investors including NEA, Flagship Ventures & Nanodimension.

Visit: http://www.blendtx.com/

Biotech Showcase™ 2015
Bone Therapeutics
Bone Therapeutics
Gosselies, Belgium
Bone Therapeutics is the most advanced regenerative therapy company focused on bone diseases and orthopaedic conditions. The company develops unique autologous (PREOB®) and a...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Bone Therapeutics

Bone Therapeutics
Track: A
City: Gosselies
Country: Belgium
Ownership: PRIVATE
Schedule information will be posted soon
Bone Therapeutics is the most advanced regenerative therapy company focused on bone diseases and orthopaedic conditions. The company develops unique autologous (PREOB®) and allogeneic (ALLOB®) osteoblastic cell therapy products offering significant advantages over existing treatments. Bone Therapeutics has two Phase III trials ongoing and is looking to meet investors and potential partners.

Visit: http://www.bonetherapeutics.com

Biotech Showcase™ 2015
Calevia
Calevia
Montreal, Quebec, Canada
Calevia Inc. is creating an entire new therapeutic platform bridging deficiencies in drug and photothermal therapy. Using the power of existing compound sensitivity and the h...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Calevia

Calevia
Track: A
City: Montreal
State: Quebec
Country: Canada
Ownership: PRIVATE
Schedule information will be posted soon
Calevia Inc. is creating an entire new therapeutic platform bridging deficiencies in drug and photothermal therapy. Using the power of existing compound sensitivity and the heating capacity of graphene, the innovative nanotechnology platform could ultimately redefine the way we treat cancer.

Visit: http://www.calevia.com

Biotech Showcase™ 2015
Calypso Biotech SA
Calypso Biotech SA
Plan-les-Ouates, Switzerland
Calypso Biotech, a spin-off from Merck Serono, discovers and develops antibody therapies for niche indications in gastro-intestinal diseases with high unmet medical need. Our...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Calypso Biotech SA

Calypso Biotech SA
Track: B
City: Plan-les-Ouates
Country: Switzerland
Ownership: PRIVATE
Schedule information will be posted soon
Calypso Biotech, a spin-off from Merck Serono, discovers and develops antibody therapies for niche indications in gastro-intestinal diseases with high unmet medical need. Our portfolio includes two preclinical programs and we are seeking 17 Mi euro series A refinancing in order to reach PoC by 2017 for both programs.

Visit: http://www.calypsobiotech.com

Biotech Showcase™ 2015
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd.
(NYSE MKT:CANF)
Petah-Tikva, Israel
Can-Fite BioPharma (NYSE MKT: CANF; TASE: CFBI) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. T...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd.
Track: C
City: Petah-Tikva
Country: Israel
Ownership: PUBLIC
Ticker: CANF
Stock exchange: NYSE MKT
Schedule information will be posted soon
Can-Fite BioPharma (NYSE MKT: CANF; TASE: CFBI) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.

Visit: http://www.canfite.co.il/

Biotech Showcase™ 2015
Canbex Therapeutics
Canbex Therapeutics
London, United Kingdom
Canbex compound in Phase 1 aims to set a new standard in treating spasticity in multiple sclerosis, through improved tolerability. Spasticity is the uncontrollable and often ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Canbex Therapeutics

Canbex Therapeutics
Track: B
City: London
Country: United Kingdom
Ownership: PRIVATE
Schedule information will be posted soon
Canbex compound in Phase 1 aims to set a new standard in treating spasticity in multiple sclerosis, through improved tolerability. Spasticity is the uncontrollable and often crippling movement of limbs and torso. VSN16R’s USP is its lack of sedative and other disadvantages of standard agents. Lead Investor: Merck Serono Ventures.

Visit: http://canbex.co.uk

Biotech Showcase™ 2015
CANbridge Life Sciences Ltd.
CANbridge Life Sciences Ltd.
Beijing, Beijing, China
CANbridge Life Sciences in-licenses, develops and commercializes Western clinical-stage pharmaceuticals and devices in China. CANbridge has obtained exclusive license from Aza...


Share this:Email this pageShare this on LinkedInShare this on Twitter

CANbridge Life Sciences Ltd.

CANbridge Life Sciences Ltd.
Track: B
City: Beijing
State: Beijing
Country: China
Ownership: PRIVATE
Schedule information will be posted soon
CANbridge Life Sciences in-licenses, develops and commercializes Western clinical-stage pharmaceuticals and devices in China. CANbridge has obtained exclusive license from Azaya Therapeutics to develop and commercialize NSCLC treatment ATI-1123 in China and North Asia, and is continuing to seek product licensing opportunities. The Company is angel funded and will complete Series A in 2014.

Visit: http://canbridgepharma.com

Biotech Showcase™ 2015
Cardiox Corporation
Cardiox Corporation
Columbus, Ohio, United States
Cardiox Corporation is a private venture backed, diagnostic medical device start-up with recent CE Mark and 510(k) clearance beginning international and domestic commercializa...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cardiox Corporation

Cardiox Corporation
Track: A
City: Columbus
State: Ohio
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Cardiox Corporation is a private venture backed, diagnostic medical device start-up with recent CE Mark and 510(k) clearance beginning international and domestic commercialization of its first product, the Flow Detection System, for cardiac shunt detection and quantification, and its next product, for liver function testing, in clinical and regulatory development.

Visit: http://www.cardiox.com

Biotech Showcase™ 2015
Cell Medica Inc
Cell Medica Inc
London, United Kingdom
Cell Medica is developing T-cell immunotherapies for tumors and infections after hematopoietic stem cell transplantation. Cell Medica has completed enrollment in two randomize...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cell Medica Inc

Cell Medica Inc
Track: B
City: London
Country: United Kingdom
Ownership: PRIVATE
Schedule information will be posted soon
Cell Medica is developing T-cell immunotherapies for tumors and infections after hematopoietic stem cell transplantation. Cell Medica has completed enrollment in two randomized studies for cytomegalovirus infection and has one ongoing phase 1/2 study for adenovirus infection. In Q1 2014, Cell Medica will initiate a multicenter phase 2 study for the treatment of Epstein Barr virus associated lymphoma.

Visit: http://www.cellmedica.co.uk/

Biotech Showcase™ 2015
Cell2B
Cell2B
Cantanhede, Portugal
Cell2B is dedicated to treat immune unmet clinical needs. We use Mesenchymal Stromal Cells to treat Graft-versus-Host Disease and have positive outcomes in treating a pool of ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cell2B

Cell2B
Track: B
City: Cantanhede
Country: Portugal
Ownership: PRIVATE
Schedule information will be posted soon
Cell2B is dedicated to treat immune unmet clinical needs. We use Mesenchymal Stromal Cells to treat Graft-versus-Host Disease and have positive outcomes in treating a pool of 6 patients with GvHD. We have Orphan Designation and positive feedback from EMA to proceed with clinical trials.

Visit: http://www.cell2b.com

Biotech Showcase™ 2015
Cellceutix
Cellceutix
(OTCBB:CTIX)
Beverly, Massachusetts, United States
Cellceutix (CTIX) is a clinical stage biopharmaceutical company with innovative therapies in oncology, dermatology and antibiotics. Cellceutix believes it has a world class p...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cellceutix

Cellceutix
Track: C
City: Beverly
State: Massachusetts
Country: United States
Ownership: PUBLIC
Ticker: CTIX
Stock exchange: OTCBB
Schedule information will be posted soon
Cellceutix (CTIX) is a clinical stage biopharmaceutical company with innovative therapies in oncology, dermatology and antibiotics. Cellceutix believes it has a world class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix is preparing to conduct four Phase 2 clinical trials in 2014.

Visit: http://www.cellceutix.com

Biotech Showcase™ 2015
Cerecor Inc.
Cerecor Inc.
Baltimore, Maryland, United States
Cerecor Inc.is a clinical-stage biopharmaceutical company committed to becoming a leader in the development and commercialization of innovative drugs that address the needs of...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cerecor Inc.

Cerecor Inc.
Track: A
City: Baltimore
State: Maryland
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Cerecor Inc.is a clinical-stage biopharmaceutical company committed to becoming a leader in the development and commercialization of innovative drugs that address the needs of underserved patients with nervous system disorders.

Visit: http://www.cerecor.com

Biotech Showcase™ 2015
Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc.
(NASDAQ:CEMI)
Medford, New York, United States
Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $10 billion point-of-care testing market. Chembio's tw...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Chembio Diagnostics, Inc.

Chembio Diagnostics, Inc.
Track: C
City: Medford
State: New York
Country: United States
Ownership: PUBLIC
Ticker: CEMI
Stock exchange: NASDAQ
Schedule information will be posted soon
Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $10 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere, Inc. Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally and has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®), which has significant advantages over lateral-flow technology.

Visit: http://www.chembio.com

Biotech Showcase™ 2015
Chronos Therapeutics
Chronos Therapeutics
Oxford, United Kingdom
Chronos researches the diseases of ageing via the proprietary ChronoscreenTM high throughput epigenetic screen. Lead compound RDC5 was identified in the ChronoscreenTM and is ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Chronos Therapeutics

Chronos Therapeutics
Track: A
City: Oxford
Country: United Kingdom
Ownership: PRIVATE
Schedule information will be posted soon
Chronos researches the diseases of ageing via the proprietary ChronoscreenTM high throughput epigenetic screen. Lead compound RDC5 was identified in the ChronoscreenTM and is now at clinical stage. RDC5 has two target indications currently - osteoporosis and ALS (Lou Gehrig's disease). Chronos raised $13m for its neurodegeneration programme in December 2013.

Visit: http://www.chronostherapeutics.com

Biotech Showcase™ 2015
Cipher Pharmaceuticals
Cipher Pharmaceuticals
(TSX:DND)
Mississauga, Ontario, Canada
Cipher is a growing specialty pharmaceutical company with three commercial products in North America. Our Products are typically improved formulations of currently marketed dr...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cipher Pharmaceuticals

Cipher Pharmaceuticals
Track: D
City: Mississauga
State: Ontario
Country: Canada
Ownership: PUBLIC
Ticker: DND
Stock exchange: TSX
Schedule information will be posted soon
Cipher is a growing specialty pharmaceutical company with three commercial products in North America. Our Products are typically improved formulations of currently marketed drugs. We in-license a product, manage any remaining clinical development and regulatory requirements, and either out-license it to a marketing partner, or, in Canada, we may choose to market the product ourselves.

Visit: http://www.cipherpharma.com

Biotech Showcase™ 2015
Convergence Pharmaceuticals
Convergence Pharmaceuticals
Cambridge, United Kingdom
Convergence Pharmaceuticals is the world leading ion channel drug discovery and development company. The pipeline of differentiated clinical-stage compounds targets the point...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Convergence Pharmaceuticals

Convergence Pharmaceuticals
Track: B
City: Cambridge
Country: United Kingdom
Ownership: PRIVATE
Schedule information will be posted soon
Convergence Pharmaceuticals is the world leading ion channel drug discovery and development company. The pipeline of differentiated clinical-stage compounds targets the points of convergence in chronic pain signalling through modulation of specific ion-channels. Convergence is well funded and raised US$35.4 million in Series A financing from a syndicate of leading European and US VCs including SVLS, New Leaf and Apposite.

Visit: http://www.convergencepharma.com/

Biotech Showcase™ 2015
Coyote Pharmaceuticals
Coyote Pharmaceuticals
Menlo Park, California, United States
Leader in developing geranylgeranylacetone (GGA) for multiple applications/indications including the sublingual delivery of injectable products and as product candidates for n...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Coyote Pharmaceuticals

Coyote Pharmaceuticals
Track: B
City: Menlo Park
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Leader in developing geranylgeranylacetone (GGA) for multiple applications/indications including the sublingual delivery of injectable products and as product candidates for neurodegenerative diseases. Its GGA franchise has shown significant pre-clinical success. With over 60 patent applications and expanding pharmaceutical partnerships, Coyote is preparing for clinical trials and poised for accelerating growth.

Visit: http://www.coyotepharma.com

Biotech Showcase™ 2015
Crescendo Biologics Ltd
Crescendo Biologics Ltd
Cambridge, United Kingdom
This month Crescendo raised $28m in a Series A financing led by Imperial Innovations, and including new investor Astellas Venture Management, and founding seed investor Sofinn...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Crescendo Biologics Ltd

Crescendo Biologics Ltd
Track: A
City: Cambridge
Country: United Kingdom
Ownership: PRIVATE
Schedule information will be posted soon
This month Crescendo raised $28m in a Series A financing led by Imperial Innovations, and including new investor Astellas Venture Management, and founding seed investor Sofinnova Partners. The funds raised will be used to advance Crescendo’s in-house development programmes in inflammation and oncology utilising its best-in-class VH fragment discovery platform centre

Visit: http://www.crescendobiologics.com/

Biotech Showcase™ 2015
Crystal Bioscience
Crystal Bioscience
Emeryville, California, United States
Crystal Bioscience is an antibody discovery company that has a track record of success with difficult targets, such as GPCRs and ion channels, that have proven intractable wit...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Crystal Bioscience

Crystal Bioscience
Track: A
City: Emeryville
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Crystal Bioscience is an antibody discovery company that has a track record of success with difficult targets, such as GPCRs and ion channels, that have proven intractable with conventional discovery platforms. Our collaborators include biotechnology, diagnostics, and pharmaceutical companies.

Visit: http://www.crystalbioscience.com

Biotech Showcase™ 2015
CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services
Blue Ash, Ohio, United States
CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consult...


Share this:Email this pageShare this on LinkedInShare this on Twitter

CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services
Track: A
City: Blue Ash
State: Ohio
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations.

Visit: http://www.ctifacts.com

Biotech Showcase™ 2015
Cyclacel
Cyclacel
(NASDAQ:CYCC)
Berkeley Heights, New Jersey, United States
Biopharmaceutical company developing oral therapies for cancer and other serious diseases targeting cell cycle control mechanisms. Oral sapacitabine capsules is in Phase 3 und...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cyclacel

Cyclacel
Track: D
City: Berkeley Heights
State: New Jersey
Country: United States
Ownership: PUBLIC
Ticker: CYCC
Stock exchange: NASDAQ
Schedule information will be posted soon
Biopharmaceutical company developing oral therapies for cancer and other serious diseases targeting cell cycle control mechanisms. Oral sapacitabine capsules is in Phase 3 under an SPA with FDA as front-line treatment for elderly AML, and Phase 2 for MDS, CLL and solid tumors and in particular those carrying gBRCA mutations.

Visit: http://www.cyclacel.com

Biotech Showcase™ 2015
Cynapsus Therapeutics Inc
Cynapsus Therapeutics Inc
(OTCQX:CYNAF)
Toronto, Ontario, Canada
Cynapsus is a specialty pharmaceutical company developing a convenient and easy to use sublingual thin film strip for the acute rescue of “off” motor symptoms of Parkinson...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cynapsus Therapeutics Inc

Cynapsus Therapeutics Inc
Track: D
City: Toronto
State: Ontario
Country: Canada
Ownership: PUBLIC
Ticker: CYNAF
Stock exchange: OTCQX
Schedule information will be posted soon
Cynapsus is a specialty pharmaceutical company developing a convenient and easy to use sublingual thin film strip for the acute rescue of “off” motor symptoms of Parkinson’s disease. Over 1 million people in the U.S. and an estimated 5 million globally suffer from Parkinson's disease. A recent study and results of the Company’s Global 500 Neurologists Survey, estimate between 25 percent and 50 percent of patients experience “off” episodes in which they impaired movement or speaking capabilities.

Visit: http://www.cynapsus.ca

Biotech Showcase™ 2015
CytoDyn Inc.
CytoDyn Inc.
(OTCQB:CYDY)
Vancouver, Washington, United States
CytoDyn is a biotechnology company developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for treatment and prevention of...


Share this:Email this pageShare this on LinkedInShare this on Twitter

CytoDyn Inc.

CytoDyn Inc.
Track: D
City: Vancouver
State: Washington
Country: United States
Ownership: PUBLIC
Ticker: CYDY
Stock exchange: OTCQB
Schedule information will be posted soon
CytoDyn is a biotechnology company developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for treatment and prevention of HIV. The Company has one of the leading mAbs under development for HIV infection PRO 140 which is a Late Stage II humanized mAb with demonstrated antiviral activity in man. PRO 140 blocks HIV co-receptor CCR5 and clinical trials have shown it can significantly reduce viral burden in people infected with HIV.

Visit: http://www.cytodyn.com

Biotech Showcase™ 2015
Cytori Therapeutics
Cytori Therapeutics
(NASDAQ:CYTX)
San Diego, California, United States
Cytori Therapeutics develops cell therapies based on regenerative cells found within adipose tissue. In the U.S. we are conducting clinical research for the treatment of chron...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cytori Therapeutics

Cytori Therapeutics
Track: C
City: San Diego
State: California
Country: United States
Ownership: PUBLIC
Ticker: CYTX
Stock exchange: NASDAQ
Schedule information will be posted soon
Cytori Therapeutics develops cell therapies based on regenerative cells found within adipose tissue. In the U.S. we are conducting clinical research for the treatment of chronic ischemic heart failure and are developing a treatment for thermal burns under a contract from BARDA, a division of the U.S. government.

Visit: http://www.cytori.com

Biotech Showcase™ 2015
CytoSorbents Corporation
CytoSorbents Corporation
(OTCBB:CTSO)
Monmouth Junction, New Jersey, United States
CytoSorbents Corporation (OTCBB: CTSO) is a critical care focused immunotherapy company using blood purification to treat life-threatening illnesses.  Its flagship product Cy...


Share this:Email this pageShare this on LinkedInShare this on Twitter

CytoSorbents Corporation

CytoSorbents Corporation
Track: C
City: Monmouth Junction
State: New Jersey
Country: United States
Ownership: PUBLIC
Ticker: CTSO
Stock exchange: OTCBB
Schedule information will be posted soon
CytoSorbents Corporation (OTCBB: CTSO) is a critical care focused immunotherapy company using blood purification to treat life-threatening illnesses.  Its flagship product CytoSorb® is E.U. approved with sales as a first-in-class extracorporeal cytokine filter, designed to reduce uncontrolled inflammation and prevent or treat organ failure in sepsis, ARDS, trauma, burn injury, pancreatitis, and many others.

Visit: http://www.cytosorbents.com

Biotech Showcase™ 2015
DioGenix
DioGenix
Rockville, Maryland, United States
DioGenix (DGx) is developing and commercializing proprietary molecular tests to aid in difficult healthcare decisions associated with neurological disease.  Our lead product,...


Share this:Email this pageShare this on LinkedInShare this on Twitter

DioGenix

DioGenix
Track: B
City: Rockville
State: Maryland
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
DioGenix (DGx) is developing and commercializing proprietary molecular tests to aid in difficult healthcare decisions associated with neurological disease.  Our lead product, MSPrecise®, is a first-in-class next-generation sequencing assay that identifies patients with multiple sclerosis at first clinical presentation.  DGx recently raised over $3M to complete this trial and make this patented test available to patients.

Visit: http://diogenix.com

Biotech Showcase™ 2015
DiscGenics
DiscGenics
Salt Lake City, Utah, United States
DiscGenics is a biotechnology company developing advanced spinal therapeutics to treat patients with diseases of the intervertebral disc.  We are currently developing IDC...


Share this:Email this pageShare this on LinkedInShare this on Twitter

DiscGenics

DiscGenics
Track: B
City: Salt Lake City
State: Utah
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
DiscGenics is a biotechnology company developing advanced spinal therapeutics to treat patients with diseases of the intervertebral disc.  We are currently developing IDCT, a novel off-the-shelf injectable therapeutic based on stem/progenitor cell science to treat lower back pain.  We are currently seeking funding for our first-in-human Phase I/II clinical study.

Visit: http://www.discgenics.com

Biotech Showcase™ 2015
DNAtrix, Inc.
DNAtrix, Inc.
San Diego, California, United States
DNAtrix is developing a new class of oncolytic viruses for cancer.  Its lead clinical candidate DNX-2401 is a retinoblastoma-pathway drug entering Phase II clinical trials f...


Share this:Email this pageShare this on LinkedInShare this on Twitter

DNAtrix, Inc.

DNAtrix, Inc.
Track: B
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
DNAtrix is developing a new class of oncolytic viruses for cancer.  Its lead clinical candidate DNX-2401 is a retinoblastoma-pathway drug entering Phase II clinical trials for recurrent glioblastoma, with promising Phase I results. The company is raising funds to advance its clinical program for brain tumors and other important indications.

Visit: http://www.dnatrix.com

Biotech Showcase™ 2015
Domainex Ltd
Domainex Ltd
Cambridge, United Kingdom
Domainex is targeting TBK1/IKKe for the treatment of cancer and COPD and other inflammatory diseases.  The company’s program is approaching candidate selection with inhibit...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Domainex Ltd

Domainex Ltd
Track: B
City: Cambridge
Country: United Kingdom
Ownership: PRIVATE
Schedule information will be posted soon
Domainex is targeting TBK1/IKKe for the treatment of cancer and COPD and other inflammatory diseases.  The company’s program is approaching candidate selection with inhibitors showing activity in cells signalling by IL 17 and have also demonstrated efficacy in disrupting inflammation caused by LPs.  The company’s current investors include:  Longbow Capital, Bury Fitzwilliam Lay and UCLB. 

Visit: http://www.domainex.co.uk/

Biotech Showcase™ 2015
Dynamis Pharmaceuticals, Inc.
Dynamis Pharmaceuticals, Inc.
Jenkintown, Pennsylvania, United States
Dynamis Pharmaceuticals, Inc. is developing proprietary small molecule, oral drugs to treat certain diseases associated with diabetic complications. To date Dynamis validated ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Dynamis Pharmaceuticals, Inc.

Dynamis Pharmaceuticals, Inc.
Track: B
City: Jenkintown
State: Pennsylvania
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Dynamis Pharmaceuticals, Inc. is developing proprietary small molecule, oral drugs to treat certain diseases associated with diabetic complications. To date Dynamis validated the Target, identified several HTS hits and performed XRay crystallography. Dynamis has raised about $8M from angel investors and federal funding.

Visit: http://www.dynamis-therapeutics.com

Biotech Showcase™ 2015
Eboo Pharmaceuticals Inc.
Eboo Pharmaceuticals Inc.
Durham, North Carolina, United States
EPI is raising $20M series A support to drive our lead compound for treating Parkinson's Disease through human proof of concept over the next 3 years . EPI has already receive...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Eboo Pharmaceuticals Inc.

Eboo Pharmaceuticals Inc.
Track: B
City: Durham
State: North Carolina
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
EPI is raising $20M series A support to drive our lead compound for treating Parkinson's Disease through human proof of concept over the next 3 years . EPI has already received $1.5M non-dilutive funding from the MJ Fox Foundation and is pursuing other non-dilutive funding opportunities.

Visit: http://www.eboopharma.com

Biotech Showcase™ 2015
Embera NeuroTherapeutics, Inc.
Embera NeuroTherapeutics, Inc.
Sudbury, Massachusetts, United States
Embera is developing a novel, patented drug combination (EMB-001) to address significant unmet needs in smoking cessation and cocaine dependence whose markets together exceed ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Embera NeuroTherapeutics, Inc.

Embera NeuroTherapeutics, Inc.
Track: A
City: Sudbury
State: Massachusetts
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Embera is developing a novel, patented drug combination (EMB-001) to address significant unmet needs in smoking cessation and cocaine dependence whose markets together exceed $2B. Embera will submit an IND for EMB-001 in Q1, 2014 and initiate a phase 1 study in otherwise healthy smokers.

Visit: http://www.emberaneuro.com

Biotech Showcase™ 2015
Endoceutics
Endoceutics
Quebec, Quebec, Canada
Final Phase III clinical trial with prasterone, a non estrogenic treatment of vulvovaginal atrophy + 4 Phase III indications (vasomotor symptoms + prevention of osteoporosis ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Endoceutics

Endoceutics
Track: B
City: Quebec
State: Quebec
Country: Canada
Ownership: PRIVATE
Schedule information will be posted soon
Final Phase III clinical trial with prasterone, a non estrogenic treatment of vulvovaginal atrophy + 4 Phase III indications (vasomotor symptoms + prevention of osteoporosis – endometriosis – male hypogonadism) + 2 Phase I/II products against prostate cancer

Visit: http://www.endoceutics.com

Biotech Showcase™ 2015
Enteris BioPharma, Inc.
Enteris BioPharma, Inc.
Boonton, New Jersey, United States
Enteris is a drug delivery company offering formulation solutions to partners around our proprietary delivery platform. Its delivery technology has been validated in late stag...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Enteris BioPharma, Inc.

Enteris BioPharma, Inc.
Track: A
City: Boonton
State: New Jersey
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Enteris is a drug delivery company offering formulation solutions to partners around our proprietary delivery platform. Its delivery technology has been validated in late stage clinical trials to enable the oral delivery of impermeable and insoluble molecules, including peptides, in an enteric coated tablet. Enteris has proven its ability to effectively deliver a variety of molecules across multiple therapeutic indications.

Visit: http://www.enterisbiopharma.com

Biotech Showcase™ 2015
Etubics Corporation
Etubics Corporation
Seattle, Washington, United States
Etubics Corporation utilizes the vector based Etubics Platform which is stealth to the immune system. The simple-to-use injectable induces a long lasting, active immune respon...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Etubics Corporation

Etubics Corporation
Track: B
City: Seattle
State: Washington
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Etubics Corporation utilizes the vector based Etubics Platform which is stealth to the immune system. The simple-to-use injectable induces a long lasting, active immune response against cancers and infectious diseases. Etubics has completed a Phase I/Phase IIa clinical trial with ETBX-011, an immunotherapeutic for end-stage colorectal cancer patients.

Visit: http://www.etubics.com

Biotech Showcase™ 2015
Evoke Pharma
Evoke Pharma
(NASDAQ:EVOK)
San Diego, California, United States
Evoke Pharma is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company is developing EV...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Evoke Pharma

Evoke Pharma
Track: D
City: San Diego
State: California
Country: United States
Ownership: PUBLIC
Ticker: EVOK
Stock exchange: NASDAQ
Schedule information will be posted soon
Evoke Pharma is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with diabetic gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms.

Visit: http://www.evokepharma.com

Biotech Showcase™ 2015
Fibralign Corporation
Fibralign Corporation
Union City, California, United States
Fibralign develops biomedical devices incorporating its proprietary scaffolding technology, creating significant value for applications in regenerative medicine and tissue eng...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Fibralign Corporation

Fibralign Corporation
Track: B
City: Union City
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Fibralign develops biomedical devices incorporating its proprietary scaffolding technology, creating significant value for applications in regenerative medicine and tissue engineering. Fibralign’s first product, BioBridge™, targets unaddressed ischemia and lymphedema conditions with a target patient US/Global market of >10M/130M patients and >$5B potential.

Visit: http://www.fibralignbio.com

Biotech Showcase™ 2015
Flowonix Medical Inc.
Flowonix Medical Inc.
Mt. Olive, New Jersey, United States
Flowonix is a medical device company dedicated to helping those who suffer from chronic disorders. Our team has decades of experience developing unique and reliable medical de...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Flowonix Medical Inc.

Flowonix Medical Inc.
Track: B
City: Mt. Olive
State: New Jersey
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Flowonix is a medical device company dedicated to helping those who suffer from chronic disorders. Our team has decades of experience developing unique and reliable medical devices to improve lifestyles. Using one of a kind technology, Flowonix has developed an implantable drug pump designed to deliver therapeutic drugs into the spine to relieve a variety of chronic disorders and help patients return to normal lives.

Visit: http://www.flowonix.com

Biotech Showcase™ 2015
FLUOROPHARMA MEDICAL INC.
FLUOROPHARMA MEDICAL INC.
(OTCBB:FPMI)
Montclair, New Jersey, United States
FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary Pet imaging products to evaluate cardiac disease at the cellular and molecu...


Share this:Email this pageShare this on LinkedInShare this on Twitter

FLUOROPHARMA MEDICAL INC.

FLUOROPHARMA MEDICAL INC.
Track: D
City: Montclair
State: New Jersey
Country: United States
Ownership: PUBLIC
Ticker: FPMI
Stock exchange: OTCBB
Schedule information will be posted soon
FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary Pet imaging products to evaluate cardiac disease at the cellular and molecular levels. FluoroPharma’s initial focus is the development of breakthrough positron emission tomography (PET) imaging agents and is advancing two products currently in phase II clinical trials.

Visit: http://www.fluoropharma.com/

Biotech Showcase™ 2015
FPRT Bio
FPRT Bio
Scranton, Pennsylvania, United States
FPRT Bio is developing XPRo1595, a selective inhibitor of soluble TNF that is anti-inflammatory, neuroprotective and crosses the BBB, for the treatment of ALS and Parkinson’...


Share this:Email this pageShare this on LinkedInShare this on Twitter

FPRT Bio

FPRT Bio
Track: A
City: Scranton
State: Pennsylvania
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
FPRT Bio is developing XPRo1595, a selective inhibitor of soluble TNF that is anti-inflammatory, neuroprotective and crosses the BBB, for the treatment of ALS and Parkinson’s disease.   FPRT is raising funds to supplement support provided by Wellcome Trust and MJ Fox Foundation to complete Phase I POC clinical trials.

Visit: http://www.fprtbio.com

Biotech Showcase™ 2015
G1 Therapeutics
G1 Therapeutics
Chapel Hill, North Carolina, United States
G1 Therapeutics (G1) is developing highly potent and selective next generation CDK4/6 inhibitors to harness cell cycle control for the treatment of cancer and other diseases. ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

G1 Therapeutics

G1 Therapeutics
Track: A
City: Chapel Hill
State: North Carolina
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
G1 Therapeutics (G1) is developing highly potent and selective next generation CDK4/6 inhibitors to harness cell cycle control for the treatment of cancer and other diseases. These molecules have demonstrated excellent preclinical activity as antineoplastics and molecularly targeted organ protectants. G1 plans to file its first IND in Q3 2014.

Visit: http://www.g1therapeutics.com/

Biotech Showcase™ 2015
Gamma Vaccines Pty Ltd
Gamma Vaccines Pty Ltd
Canberra, Australian Capital Territory, Australia
Gamma Vaccines uses gamma irradiation – a sterilization procedure – to produce superior vaccines that offer broader spectrum immunity. This remarkably simple procedure has...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Gamma Vaccines Pty Ltd

Gamma Vaccines Pty Ltd
Track: A
City: Canberra
State: Australian Capital Territory
Country: Australia
Ownership: PRIVATE
Schedule information will be posted soon
Gamma Vaccines uses gamma irradiation – a sterilization procedure – to produce superior vaccines that offer broader spectrum immunity. This remarkably simple procedure has enabled development of influenza vaccines that are highly cross-protective against different flu strains (including Bird flu). Current investors include a major Asian pharmaceutical company and private investors.

Visit: http://www.gammavaccines.com

Biotech Showcase™ 2015
Genalyte, Inc.
Genalyte, Inc.
San Diego, California, United States
Genalyte has developed a photonic, multiplex, detection technology ("Maverick"). It has broad application potential, and has been demonstrated to detect and measure blood biom...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Genalyte, Inc.

Genalyte, Inc.
Track: A
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Genalyte has developed a photonic, multiplex, detection technology ("Maverick"). It has broad application potential, and has been demonstrated to detect and measure blood biomarkers, proteins, virus particles, and nucleic acids. It provides a quantitative output that has already been validated at 128-plex, can scale to thousands, and has been demonstrated with complex media including whole blood, serum, and cell lysate on a few microliters of sample in about 10 mins for a cost of a few dollars.

Visit: http://www.genalyte.com

Biotech Showcase™ 2015
GENFIT
GENFIT
(Euronext:ALGFT)
Loos, France
GENFIT is at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular foc...


Share this:Email this pageShare this on LinkedInShare this on Twitter

GENFIT

GENFIT
Track: D
City: Loos
Country: France
Ownership: PUBLIC
Ticker: ALGFT
Stock exchange: Euronext
Schedule information will be posted soon
GENFIT is at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. GENFIT has developed a pipeline of proprietary products, of which the most advanced, GFT505, is currently in a phase IIb clinical trial for the treatment of NASH.

Visit: http://www.genfit.com

Biotech Showcase™ 2015
Genoa Pharmaceuticals
Genoa Pharmaceuticals
San Diego, California, United States
Genoa Pharmaceuticals is developing treatments for Idiopathic Pulmonary Fibrosis. The company’s lead asset (GP-101; inhaled pirfenidone) is in entering clinic-enabling toxic...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Genoa Pharmaceuticals

Genoa Pharmaceuticals
Track: A
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Genoa Pharmaceuticals is developing treatments for Idiopathic Pulmonary Fibrosis. The company’s lead asset (GP-101; inhaled pirfenidone) is in entering clinic-enabling toxicology. Compared to oral, inhalation offers superior efficacy and holds promise to reduce oral-associated side effects.

Visit: http://www.genoapharma.com

Biotech Showcase™ 2015
Gensight Biologics
Gensight Biologics
Paris, France
Gensight develops gene therapy-based treatments to prevent sight loss and restore vision in patients with retinal degenerative diseases. First product will enter Phase1 trial ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Gensight Biologics

Gensight Biologics
Track: B
City: Paris
Country: France
Ownership: PRIVATE
Schedule information will be posted soon
Gensight develops gene therapy-based treatments to prevent sight loss and restore vision in patients with retinal degenerative diseases. First product will enter Phase1 trial in February 2014, expecting a first conditional approval by end 2016. The company raised € 32M Series A in March 2013, co led by Novartis, Abingworth, Versant and Index.

Visit: http://www.gensight-biologics.com/

Biotech Showcase™ 2015
GICARE PHARMA INC
GICARE PHARMA INC
Montreal, Quebec, Canada
gIcare pharma is VC backed by Genesys Capital and Forbion Capital Partners. The Company is looking for new investors in order to complete a 20M$ Series B financing in view of ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

GICARE PHARMA INC

GICARE PHARMA INC
Track: B
City: Montreal
State: Quebec
Country: Canada
Ownership: PRIVATE
Schedule information will be posted soon
gIcare pharma is VC backed by Genesys Capital and Forbion Capital Partners. The Company is looking for new investors in order to complete a 20M$ Series B financing in view of Phase 3 trials with GIC-1001. Current investors will reinvest in the Series B round.

Visit: http://www.gicarepharma.com

Biotech Showcase™ 2015
HanAll BioPharma Co., Ltd
HanAll BioPharma Co., Ltd
(Korea Exchange (KRX):9420)
Seoul, Korea, South
HanAll BioPharma Co., Ltd is a leading R&D oriented Korean biopharmaceutical company. HanAll has been developing innovative new drug pipelines in the areas of protein therapeu...


Share this:Email this pageShare this on LinkedInShare this on Twitter

HanAll BioPharma Co., Ltd

HanAll BioPharma Co., Ltd
Track: D
City: Seoul
Country: Korea, South
Ownership: PUBLIC
Ticker: 9420
Stock exchange: Korea Exchange (KRX)
Schedule information will be posted soon
HanAll BioPharma Co., Ltd is a leading R&D oriented Korean biopharmaceutical company. HanAll has been developing innovative new drug pipelines in the areas of protein therapeutics/antibodies, anticancer therapies targeting cancer metabolism, and ophthalmology. HanAll is seeking global partners for above programs.

Visit: http://www.hanallbiopharma.com/

Biotech Showcase™ 2015
Hansa Medical AB
Hansa Medical AB
(NASDAQ OMX:HMED)
Lund, Sweden
Hansa Medical targets pathogenic IgG antibodies preventing and treating antibody mediated rejection in solid organ transplantation. The company’s lead candidate is IdeS, an ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Hansa Medical AB

Hansa Medical AB
Track: D
City: Lund
Country: Sweden
Ownership: PUBLIC
Ticker: HMED
Stock exchange: NASDAQ OMX
Schedule information will be posted soon
Hansa Medical targets pathogenic IgG antibodies preventing and treating antibody mediated rejection in solid organ transplantation. The company’s lead candidate is IdeS, an IgG specific enzyme in Phase I/II clinical development.  The company´s main investors are Sweden based venture capital firm NXT2B and Farstorp Invest. 

Visit: http://www.hansamedical.com/

Biotech Showcase™ 2015
Harbor Therapeutics, Inc.
Harbor Therapeutics, Inc.
San Diego, California, United States
Harbor is focused on Parkinson’s L-DOPA dyskinesia, with a re-purposed Phase II compound, HE3286, which is an orally bioavailable, blood-brain-barrier permeable, anti-inflam...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Harbor Therapeutics, Inc.

Harbor Therapeutics, Inc.
Track: A
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Harbor is focused on Parkinson’s L-DOPA dyskinesia, with a re-purposed Phase II compound, HE3286, which is an orally bioavailable, blood-brain-barrier permeable, anti-inflammatory agent with a unique MOA. MJFF sponsored studies show oral HE3286 is active and neuroprotective in monkeys with Parkinson’s L-DOPA dyskinesia. HE3286 is active in other neurodegenerative models.

Visit: http://www.Harbortx.com

Biotech Showcase™ 2015
Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology
(NASDAQ:HART)
Holliston, Massachusetts, United States
HART makes regenerated organs for transplant. We have eight successful human surgeries for regenerated tracheas. We have begun a clinical trial in Russia. We are NASDAQ listed...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology
Track: C
City: Holliston
State: Massachusetts
Country: United States
Ownership: PUBLIC
Ticker: HART
Stock exchange: NASDAQ
Schedule information will be posted soon
HART makes regenerated organs for transplant. We have eight successful human surgeries for regenerated tracheas. We have begun a clinical trial in Russia. We are NASDAQ listed. We expect to raise additional capital to advance both our trachea transplant product and regenerated esophagus, heart valve and lung transplants.

Visit: http://www.HARTregen.com

Biotech Showcase™ 2015
Hatchtech Pty Ltd
Hatchtech Pty Ltd
Camberwell, Victoria, Australia
Hatchtech is a private, Australian company with a Phase 3 development asset, currently seeking commercialization partners for the US and Global. The company is fully funded t...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Hatchtech Pty Ltd

Hatchtech Pty Ltd
Track: B
City: Camberwell
State: Victoria
Country: Australia
Ownership: PRIVATE
Schedule information will be posted soon
Hatchtech is a private, Australian company with a Phase 3 development asset, currently seeking commercialization partners for the US and Global. The company is fully funded through to NDA approval.

Visit: http://www.hatchtech.com.au

Biotech Showcase™ 2015
Heat Biologics, Inc.
Heat Biologics, Inc.
(NASDAQ:HTBX)
Chapel Hill, North Carolina, United States
Heat Biologics, a clinical-stage biopharmaceutical company, develops novel, "off-the-shelf" ImPACT Therapy vaccines for cancer that deliver live, genetically-modified, irradia...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Heat Biologics, Inc.

Heat Biologics, Inc.
Track: C
City: Chapel Hill
State: North Carolina
Country: United States
Ownership: PUBLIC
Ticker: HTBX
Stock exchange: NASDAQ
Schedule information will be posted soon
Heat Biologics, a clinical-stage biopharmaceutical company, develops novel, "off-the-shelf" ImPACT Therapy vaccines for cancer that deliver live, genetically-modified, irradiated human cells reprogrammed to "pump out" cancer-associated antigens with immune adjuvant, gp96, activating patients’ immune systems to kill cancerous cells. Heat has two clinical study ready product candidates, HS-110 (bladder cancer) and HS-410 (lung cancer).

Visit: http://www.heatbio.com/

Biotech Showcase™ 2015
HedgePath Pharmaceuticals, Inc.
HedgePath Pharmaceuticals, Inc.
(OTCQB:HPPI)
Tampa, Florida, United States
HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company intending to repurpose the FDA approved antifungal itraconazole as a treatment for cancer with a ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

HedgePath Pharmaceuticals, Inc.

HedgePath Pharmaceuticals, Inc.
Track: D
City: Tampa
State: Florida
Country: United States
Ownership: PUBLIC
Ticker: HPPI
Stock exchange: OTCQB
Schedule information will be posted soon
HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company intending to repurpose the FDA approved antifungal itraconazole as a treatment for cancer with a patented re-formulation known as SUBA-Itraconazole, which has clinically demonstrated greater bioavailability over the generic. Based upon promising anti-cancer results demonstrated in physician-sponsored studies, HedgePath intends to launch Ph II trials for lung, skin and prostate cancers during first-half 2014.

Visit: http://www.hedgepathpharma.com

Biotech Showcase™ 2015
Hemispherx BioPharma
Hemispherx BioPharma
(NYSE MKT:HEB)
Philadelphia, Pennsylvania, United States
Immunologic and antiviral biopharmaceutical company with one approved product (Alferon) and 1 pending approval (Ampligen) in the US and elsewhere with both products having sub...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Hemispherx BioPharma

Hemispherx BioPharma
Track: C
City: Philadelphia
State: Pennsylvania
Country: United States
Ownership: PUBLIC
Ticker: HEB
Stock exchange: NYSE MKT
Schedule information will be posted soon
Immunologic and antiviral biopharmaceutical company with one approved product (Alferon) and 1 pending approval (Ampligen) in the US and elsewhere with both products having substantial clinical and bio defense markets, each manufactured in the company's that free fully owned, cGMP facility in New Brunswick, New Jersey.

Visit: http://www.hemispherx.net

Biotech Showcase™ 2015
Ikaria, Inc.
Ikaria, Inc.
Hampton, New Jersey, United States
Ikaria focuses on innovative therapies designed to address the significant needs of critically ill patients.  Ikaria currently is developing the Bioabsorbable Cardiac Matrix ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Ikaria, Inc.

Ikaria, Inc.
Track: A
City: Hampton
State: New Jersey
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Ikaria focuses on innovative therapies designed to address the significant needs of critically ill patients.  Ikaria currently is developing the Bioabsorbable Cardiac Matrix (BCM) device for the prevention of ventricular remodeling and subsequent congestive heart failure following acute myocardial infarction. A CE Mark registration trial for BCM is underway.

Visit: http://www.ikaria.com

Biotech Showcase™ 2015
Immune System Therapeutics Ltd.
Immune System Therapeutics Ltd.
Sydney, New South Wales, Australia
IST is an antibody development company focused on hematological malignancies. Investor capital will be applied to the first-in-class mAb, IST-1097, global phase 2b trial which...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Immune System Therapeutics Ltd.

Immune System Therapeutics Ltd.
Track: A
City: Sydney
State: New South Wales
Country: Australia
Ownership: PRIVATE
Schedule information will be posted soon
IST is an antibody development company focused on hematological malignancies. Investor capital will be applied to the first-in-class mAb, IST-1097, global phase 2b trial which has worldwide KOL support. Interim Phase 2b data will be available in 18-24 months, at which point the company plans to seek liquidity for investors.

Visit: http://www.istl.com.au

Biotech Showcase™ 2015
ImmunGene, Inc.
ImmunGene, Inc.
Thousand Oaks, California, United States
ImmunGene is a development stage cancer biotherapeutic company. The drugs candidates engineering by ImmunGene are fusion of cytokines and other immune molecules with antibodie...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ImmunGene, Inc.

ImmunGene, Inc.
Track: B
City: Thousand Oaks
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
ImmunGene is a development stage cancer biotherapeutic company. The drugs candidates engineering by ImmunGene are fusion of cytokines and other immune molecules with antibodies, These antibody-fusion molecules are designed in such a way that their effect is more tolerated to non-targeted, however toxic to the targeted tissue. ImmunGene and its JV partner plan to begin clinical trial with the lead candidate in the later part of 2014.

Visit: http://www.immungene.com

Biotech Showcase™ 2015
ImmunID
ImmunID
ImmunID is a pioneer of immune molecular diagnostics aiming to set the global immune diagnostics standard. Its clinical product ImmunTraCkeR evaluates the T cell repertoire di...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ImmunID

ImmunID
Track: A
Ownership: PRIVATE
Schedule information will be posted soon
ImmunID is a pioneer of immune molecular diagnostics aiming to set the global immune diagnostics standard. Its clinical product ImmunTraCkeR evaluates the T cell repertoire diversity at the genomic level. The company is ISO9001/ISO13485 accredited and provides testing worldwide to leading clinical centers and blue-chip pharmaceutical companies.

Visit: http://www.immunid.com/

Biotech Showcase™ 2015
Immunocore
Immunocore
Abingdon, United Kingdom
Privately funded. Founded in 2008, Immunocore traces its roots to Avidex, which was founded in 1999 as a spin-out from the University of Oxford to develop novel T Cell Recepto...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Immunocore

Immunocore
Track: A
City: Abingdon
Country: United Kingdom
Ownership: PRIVATE
Schedule information will be posted soon
Privately funded. Founded in 2008, Immunocore traces its roots to Avidex, which was founded in 1999 as a spin-out from the University of Oxford to develop novel T Cell Receptor technology. The lead candidate, IMCgp100 is in Phase IIa and Immunocore is advancing other programmes towards the clinic. In 2013 Immunocore entered into major strategic discovery collaborations with Genentech and GSK. The ImmTACs can be manufactured at attractive costs leading to pricing flexibility.

Visit: http://www.immunocore.com

Biotech Showcase™ 2015
Immunome Inc.
Immunome Inc.
Wynnewood, Pennsylvania, United States
Immunome is a biotechnology company that uses the human immune system to discover and develop new cancer therapies. We have a proprietary technology and methodology to discove...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Immunome Inc.

Immunome Inc.
Track: B
City: Wynnewood
State: Pennsylvania
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Immunome is a biotechnology company that uses the human immune system to discover and develop new cancer therapies. We have a proprietary technology and methodology to discover and develop new functional antibodies and high affinity targets simultaneously, thereby dramatically increasing the speed, efficiency and productivity of discovering new cancer treatments.

Visit: http://www.immunomeinc.com

Biotech Showcase™ 2015
Immunovaccine Inc.
Immunovaccine Inc.
(TSX-V:IMV)
Halifax, Nova Scotia, Canada
Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVaxTM platform, a patented formulation that provides controlled...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Immunovaccine Inc.

Immunovaccine Inc.
Track: C
City: Halifax
State: Nova Scotia
Country: Canada
Ownership: PUBLIC
Ticker: IMV
Stock exchange: TSX-V
Schedule information will be posted soon
Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVaxTM platform, a patented formulation that provides controlled and prolonged exposure of antigens to the immune system.

Visit: http://www.imvaccine.com

Biotech Showcase™ 2015
ImmusanT, Inc.
ImmusanT, Inc.
Cambridge, Massachusetts, United States
ImmusanT is a Cambridge, Massachusetts-based privately held biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in i...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ImmusanT, Inc.

ImmusanT, Inc.
Track: B
City: Cambridge
State: Massachusetts
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
ImmusanT is a Cambridge, Massachusetts-based privately held biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that aim to improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and a companion diagnostic and monitoring tool to improve celiac disease management. ImmusanT’s targeted immunoth

Visit: http://www.immusant.com

Biotech Showcase™ 2015
INanoBio
INanoBio
Tempe, Arizona, United States
INanoBio is a nano-biotechnology company developing fourth-generation nanopore-based sequencer capable of sequencing the whole genome in 15 minutes, for under $100. The compan...


Share this:Email this pageShare this on LinkedInShare this on Twitter

INanoBio

INanoBio
Track: A
City: Tempe
State: Arizona
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
INanoBio is a nano-biotechnology company developing fourth-generation nanopore-based sequencer capable of sequencing the whole genome in 15 minutes, for under $100. The company is raising Series-A financing to develop the genome sequencer prototype and label-free electronic nano-sensor technology platform for drug discovery and diagnostics.

Visit: http://www.inanobio.com

Biotech Showcase™ 2015
Induce Biologics
Induce Biologics
Toronto, Ontario, Canada
Induce Biologics is a regenerative medicine company developing bioimplants for bone regeneration. The lead product candidate is a novel Bone Morphogenetic Protein (BMP) produc...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Induce Biologics

Induce Biologics
Track: A
City: Toronto
State: Ontario
Country: Canada
Ownership: PRIVATE
Schedule information will be posted soon
Induce Biologics is a regenerative medicine company developing bioimplants for bone regeneration. The lead product candidate is a novel Bone Morphogenetic Protein (BMP) product which produces a multi-phasic, gradual BMP delivery from the carrier, which has been shown to be safe and effective, using less BMP than current products.

Visit: http://inducebiologics.com/

Biotech Showcase™ 2015
Inovio Pharmaceuticals
Inovio Pharmaceuticals
(NYSE MK:INO)
Blue Bell, Pennsylvania, United States
Inovio is a phase II company developing synthetic DNA vaccines to prevent and treat cancers and infectious diseases. Our SynCon® vaccines delivered using our proprietary elec...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Inovio Pharmaceuticals

Inovio Pharmaceuticals
Track: D
City: Blue Bell
State: Pennsylvania
Country: United States
Ownership: PUBLIC
Ticker: INO
Stock exchange: NYSE MK
Schedule information will be posted soon
Inovio is a phase II company developing synthetic DNA vaccines to prevent and treat cancers and infectious diseases. Our SynCon® vaccines delivered using our proprietary electroporation technology are generating best-in-class immune responses, with therapeutic T-cells exceeding other technologies. Roche exclusively licensed Inovio’s DNA immunotherapies for prostate cancer and hepatitis B.

Visit: http://www.inovio.com

Biotech Showcase™ 2015
International Stem Cell Corporation
International Stem Cell Corporation
(OTCQB:ISCO)
Carlsbad, California, United States
ISCO is a California-based regenerative medicine company developing novel stem cell based therapies and biomedical products. ISCO's core technology can be use to create clini...


Share this:Email this pageShare this on LinkedInShare this on Twitter

International Stem Cell Corporation

International Stem Cell Corporation
Track: C
City: Carlsbad
State: California
Country: United States
Ownership: PUBLIC
Ticker: ISCO
Stock exchange: OTCQB
Schedule information will be posted soon
ISCO is a California-based regenerative medicine company developing novel stem cell based therapies and biomedical products. ISCO's core technology can be use to create clinical-grade cells and tissue for allogeneic therapy that are histocompatible with hundreds of millions of people.

Visit: http://www.internationalstemcell.com

Biotech Showcase™ 2015
ioGenetics
ioGenetics
Madison, Wisconsin, United States
ioGenetics is addressing the challenge of antibiotic resistance through the development of Directed Biocide® antibody fusions (DBAFs) which target and destroy microorganisms....


Share this:Email this pageShare this on LinkedInShare this on Twitter

ioGenetics

ioGenetics
Track: A
City: Madison
State: Wisconsin
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
ioGenetics is addressing the challenge of antibiotic resistance through the development of Directed Biocide® antibody fusions (DBAFs) which target and destroy microorganisms. Highly effective first/best in class products for Staph aureus MRSA/VISA strains will enter clinics in 2015. In development are DBAFs for cryptosporidium, Strep pneumoniae and other resistant organisms.

Visit: http://www.iogenetics.com

Biotech Showcase™ 2015
IRAD Oncology
IRAD Oncology
La Jolla, California, United States
IRAD Oncology is a start-up company with a unique, next generation radioimmunotherapeutic for the treatment of gliomas. Phase 2a data (N=72) showed a 38% increase in median OS...


Share this:Email this pageShare this on LinkedInShare this on Twitter

IRAD Oncology

IRAD Oncology
Track: A
City: La Jolla
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
IRAD Oncology is a start-up company with a unique, next generation radioimmunotherapeutic for the treatment of gliomas. Phase 2a data (N=72) showed a 38% increase in median OS when IRAD-425 was added to standard of care in newly diagnosed glioblastoma multiforme patients. Unlike previous radiotherapies, IRAD-425s formulation is a fixed IV dose which may be administered to outpatients.

Visit: http://www.iradoncology.com

Biotech Showcase™ 2015
Iroko Pharmaceuticals, Inc.
Iroko Pharmaceuticals, Inc.
Philadelphia, Pennsylvania, United States
Iroko, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, is developing a robust pipeline of lower dose NSAIDs, of which ZORVOLEX is th...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Iroko Pharmaceuticals, Inc.

Iroko Pharmaceuticals, Inc.
Track: A
City: Philadelphia
State: Pennsylvania
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Iroko, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, is developing a robust pipeline of lower dose NSAIDs, of which ZORVOLEX is the first to gain FDA approval, using proprietary SoluMatrix Fine Particle Technology™, to comply with FDA guidance to use the lowest effective dose. www.iroko.com.

Visit: http://www.iroko.com

Biotech Showcase™ 2015
Isarna Therapeutics
Isarna Therapeutics
Munich, Germany
Isarna Therapeutics is targeting the TGF-ß pathway in oncology. Isarna possesses an extensive pipeline of single entity compounds selectively inhibiting TGF-ß1, TGF-ß2 and ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Isarna Therapeutics

Isarna Therapeutics
Track: B
City: Munich
Country: Germany
Ownership: PRIVATE
Schedule information will be posted soon
Isarna Therapeutics is targeting the TGF-ß pathway in oncology. Isarna possesses an extensive pipeline of single entity compounds selectively inhibiting TGF-ß1, TGF-ß2 and TGF-ß3, and dual-modality combinations. The most advanced lead compounds will enter the clinic in 2014. The company’s investors include MIG Fonds, S-Refit, and Bayern Kapital.

Visit: http://www.isarna-therapeutics.com/

Biotech Showcase™ 2015
Kalos Therapeutics, Inc.
Kalos Therapeutics, Inc.
San Diego, California, United States
Kalos is a biomedical company focusing on hyperproliferative disorders targeting cancer and age-related macular degeneration (AMD). Our objective is to translate the natural h...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Kalos Therapeutics, Inc.

Kalos Therapeutics, Inc.
Track: A
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Kalos is a biomedical company focusing on hyperproliferative disorders targeting cancer and age-related macular degeneration (AMD). Our objective is to translate the natural hemodynamic controls and antiproliferative activities of the ANP family of peptides into therapies for unmet medical needs, reducing or eliminating side effects associated with chemotherapy while improving the Quality of Life for our patients.

Visit: http://www.kalostpx.com

Biotech Showcase™ 2015
Karus Therapeutics Ltd
Karus Therapeutics Ltd
Abingdon, United Kingdom
Karus Therapeutics is a leader in the development of innovative medicines that have breakthrough potential in treating inflammatory disease and cancer. The Company’s scienti...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Karus Therapeutics Ltd

Karus Therapeutics Ltd
Track: B
City: Abingdon
Country: United Kingdom
Ownership: PRIVATE
Schedule information will be posted soon
Karus Therapeutics is a leader in the development of innovative medicines that have breakthrough potential in treating inflammatory disease and cancer. The Company’s scientific excellence is reflected in its proprietary PI3K and HDAC6 inhibitor programmes, from which innovative small molecule drugs with significant clinical and commercial potential have been developed.

Visit: http://www.karustherapeutics.com

Biotech Showcase™ 2015
KemPharm
KemPharm
Coralville, Iowa, United States
KemPharm, Inc. is a clinical stage biopharmaceutical company focused on the development of new, safer therapies to treat pain. KemPharm’s lead clinical candidate, KP201, is ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

KemPharm

KemPharm
Track: A
City: Coralville
State: Iowa
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
KemPharm, Inc. is a clinical stage biopharmaceutical company focused on the development of new, safer therapies to treat pain. KemPharm’s lead clinical candidate, KP201, is composed of hydrocodone chemically bound to a ligand and is being developed for the treatment of acute, moderate to moderately severe pain.

Visit: http://www.kempharm.com

Biotech Showcase™ 2015
Kiadis Pharma
Kiadis Pharma
Amsterdam, Netherlands
Kiadis Pharma is a biopharmaceutical company focused on developing T-cell IMMUNOtherapies for blood cancer patients. Its lead product ATIR(tm) enables stemcell transplantatio...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Kiadis Pharma

Kiadis Pharma
Track: B
City: Amsterdam
Country: Netherlands
Ownership: PRIVATE
Schedule information will be posted soon
Kiadis Pharma is a biopharmaceutical company focused on developing T-cell IMMUNOtherapies for blood cancer patients. Its lead product ATIR(tm) enables stemcell transplantations from partially matched (haploidentical") family members. The company is currently sponsoring an international Phase II study for ATIR(tm) to confirm and extend earlier positive Phase I/II safety and efficacy data."

Visit: http://www.kiadis.com

Biotech Showcase™ 2015
KineMed
KineMed
Emeryville, California, United States
KineMed, Inc. is a commercial-stage company focused on applying its proprietary biomarker platform technology to drug development, prescription and non-prescription medical di...


Share this:Email this pageShare this on LinkedInShare this on Twitter

KineMed

KineMed
Track: A
City: Emeryville
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
KineMed, Inc. is a commercial-stage company focused on applying its proprietary biomarker platform technology to drug development, prescription and non-prescription medical diagnostics and the pairing of drugs with diagnostic biomarker tests.

Visit: http://www.kinemed.com

Biotech Showcase™ 2015
Labstyle Innovation
Labstyle Innovation
(OTCQB:DRIO)
Ramat Gan, Israel
LabStyle Innovations Corp. (OTCQB: DRIO) believes that a platform for connecting medical devices to real-time data collection and analysis tools will enable patients and healt...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Labstyle Innovation

Labstyle Innovation
Track: B
City: Ramat Gan
Country: Israel
Ownership: PUBLIC
Ticker: DRIO
Stock exchange: OTCQB
Schedule information will be posted soon
LabStyle Innovations Corp. (OTCQB: DRIO) believes that a platform for connecting medical devices to real-time data collection and analysis tools will enable patients and health providers to transform the quality of care. Labstyle's first product is Dario™, a mobile health (mHealth) platform that combines a compacy, stylish, all-in-one blood glucose meter, smart phone application, and treatment tools to support patients, doctors and health systems.

Biotech Showcase™ 2015
Lakewood-Amedex Inc.
Lakewood-Amedex Inc.
Sarasota, Florida, United States
Lakewood-Amedex is a private pharmaceutical discovery and development company with 74 issued patents and a novel gene-silencing technology platform. The company's nRNAs are or...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Lakewood-Amedex Inc.

Lakewood-Amedex Inc.
Track: A
City: Sarasota
State: Florida
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Lakewood-Amedex is a private pharmaceutical discovery and development company with 74 issued patents and a novel gene-silencing technology platform. The company's nRNAs are orally available and address anti-virals and acute and chronic human diseases. Lead products -bisphosphocins broad-spectrum anti-microbials for multiple bacterial and fungal infections.

Visit: http://www.lakewoodamedex.com

Biotech Showcase™ 2015
Leading BioSciences, Inc.
Leading BioSciences, Inc.
San Diego, California, United States
Leading BioSciences’ lead product is LB1148, a therapy designed to prevent the onset of shock and MOF via the direct administration of LB1148 into the stomach and lumen of t...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Leading BioSciences, Inc.

Leading BioSciences, Inc.
Track: B
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Leading BioSciences’ lead product is LB1148, a therapy designed to prevent the onset of shock and MOF via the direct administration of LB1148 into the stomach and lumen of the intestine.  Over 150 seriously ill, post op, cardiovascular patients have been treated outside the USA to include a Phase I study.   Clinical results are comparable to preclinical experience.  LBS has met with the FDA and will be submitting an IND Q1 2014 to enter Phase II with LB 1148 in the USA.

Visit: http://www.leadingbiosciences.com

Biotech Showcase™ 2015
Lion Biotechnologies, Inc.
Lion Biotechnologies, Inc.
(OTCBB:LBIO)
Woodland Hills, California, United States
Lion Biotechnologies (LBIO) is a cancer immunotherapy company developing adoptive cell therapy with autologous tumor infiltrating lymphocytes (TILs). Objective response rate h...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Lion Biotechnologies, Inc.

Lion Biotechnologies, Inc.
Track: C
City: Woodland Hills
State: California
Country: United States
Ownership: PUBLIC
Ticker: LBIO
Stock exchange: OTCBB
Schedule information will be posted soon
Lion Biotechnologies (LBIO) is a cancer immunotherapy company developing adoptive cell therapy with autologous tumor infiltrating lymphocytes (TILs). Objective response rate have been observed in approximately half of refractory metastatic melanoma patients treated TILs, with complete response rates near 10%. Management anticipates launching a registrational trial within 18 months.

Biotech Showcase™ 2015
Longevity Biotech, Inc
Longevity Biotech, Inc
Philadelphia, Pennsylvania, United States
Longevity Biotech is preclinical therapeutics platform company developing metabolically stabilized peptide therapeutics (“Hybridtides”) for Metabolics, Cardiovascular, Neu...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Longevity Biotech, Inc

Longevity Biotech, Inc
Track: B
City: Philadelphia
State: Pennsylvania
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Longevity Biotech is preclinical therapeutics platform company developing metabolically stabilized peptide therapeutics (“Hybridtides”) for Metabolics, Cardiovascular, Neuroscience, Oncology and Antiviral indications. Each program is focused on either first or best-in-class product profiles with well-defined mechanisms of action. Hybridtides feature remarkable protease stability, which enables long-acting duration and oral bioavailability potential.

Visit: http://www.longevitybiotech.com

Biotech Showcase™ 2015
Lorus Therapeutics
Lorus Therapeutics
(TSX:LOR)
San Diego, California, United States
Recent insights into the genetic causes of acute myeloid leukemia (AML) have created opportunity and scientific rationale for Lorus’ lead compound LOR-253, a clinical-stage ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Lorus Therapeutics

Lorus Therapeutics
Track: D
City: San Diego
State: California
Country: United States
Ownership: PUBLIC
Ticker: LOR
Stock exchange: TSX
Schedule information will be posted soon
Recent insights into the genetic causes of acute myeloid leukemia (AML) have created opportunity and scientific rationale for Lorus’ lead compound LOR-253, a clinical-stage first-in-class therapeutic with a favorable safety profile, based on the potential for LOR-253 to reactivate an essential apoptotic pathway in AML and potentially other cancers.

Visit: http://www.lorusthera.com/

Biotech Showcase™ 2015
Lysosomal Therapeutics Inc
Lysosomal Therapeutics Inc
Weston, Massachusetts, United States
Lysosomal Therapeutics Inc (LTI) is leveraging the genetic link between Gaucher and Parkinson’s Disease and is developing compounds that enhance the lysosomal glucocerebrosi...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Lysosomal Therapeutics Inc

Lysosomal Therapeutics Inc
Track: B
City: Weston
State: Massachusetts
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Lysosomal Therapeutics Inc (LTI) is leveraging the genetic link between Gaucher and Parkinson’s Disease and is developing compounds that enhance the lysosomal glucocerebrosidase enyme activity as an entirely new and potentially breakthrough class of agents for GD and PD. The company was founded by Henri Termeer, Bob carpenter and Peter Wirth, all ex-Genzyme executives and is in the process of raising its series A.

Biotech Showcase™ 2015
MabVax Therapeutics, Inc.
MabVax Therapeutics, Inc.
San Diego, California, United States
MabVax, a clinical stage oncology company, has integrated a vaccine program with an antibody discovery technology. We have discovered fully human antibodies from patients vac...


Share this:Email this pageShare this on LinkedInShare this on Twitter

MabVax Therapeutics, Inc.

MabVax Therapeutics, Inc.
Track: A
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
MabVax, a clinical stage oncology company, has integrated a vaccine program with an antibody discovery technology. We have discovered fully human antibodies from patients vaccinated in clinical trials that have desirable in vitro characteristics correlated with positive patient outcomes. Our vaccines are in POC Phase 2 clinical trials.

Visit: http://www.mabvax.com

Biotech Showcase™ 2015
Madeleine Pharmaceuticals
Madeleine Pharmaceuticals
Mount Barker, South Australia, Australia
Madeleine Pharmaceuticals has a lineage of natural peptides aimed at critical care. MP3167, a 37 amino acid peptide, is the first continuous approach to congestive heart failu...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Madeleine Pharmaceuticals

Madeleine Pharmaceuticals
Track: A
City: Mount Barker
State: South Australia
Country: Australia
Ownership: PRIVATE
Schedule information will be posted soon
Madeleine Pharmaceuticals has a lineage of natural peptides aimed at critical care. MP3167, a 37 amino acid peptide, is the first continuous approach to congestive heart failure therapy accompanying patients through hospital discharge then at home. 70 NYHA II, III and IV patients treated IV and SC had lasting reinstated cardio-renal homeostasis: diuresis with improved cardiac function; renal sparing without symptomatic hypotension. Continuum HF, Phase II begins Q1 2014 in 65 patients.

Visit: http://www.madeleine-pharma.com

Biotech Showcase™ 2015
Makindus, Inc
Makindus, Inc
Doylestown, Pennsylvania, United States
Makindus is a privately held clinical stage company developing treatment for rare genetic ocular disorders. Primary indication is juvenile macular degeneration that qualifies ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Makindus, Inc

Makindus, Inc
Track: B
City: Doylestown
State: Pennsylvania
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Makindus is a privately held clinical stage company developing treatment for rare genetic ocular disorders. Primary indication is juvenile macular degeneration that qualifies for an orphan indication. The company has world wide exclusive license for the indication that is complemented by novel formulation technologies.

Visit: http://www.makindus.com

Biotech Showcase™ 2015
Mariam Medical, Inc
Mariam Medical, Inc
River Forest, Illinois, United States
Mariam Medical Inc. is an emerging biotechnology company focused on bringing RNAi-based cancer and broad spectrum antiviral therapeutics (BSAV) to market: Mariam Medical is de...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Mariam Medical, Inc

Mariam Medical, Inc
Track: A
City: River Forest
State: Illinois
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Mariam Medical Inc. is an emerging biotechnology company focused on bringing RNAi-based cancer and broad spectrum antiviral therapeutics (BSAV) to market: Mariam Medical is developing RNAi (“gene silencing”) based therapeutics against genetically-defined targets in multiple cancer areas, including Hepatocellular Carcinoma (HCC), T cell leukemia, breast, prostate, ovarian, thyroid, melanoma, and neuro and glioblastoma cancers.

Visit: http://www.mariammedical.com

Biotech Showcase™ 2015
Marina Biotech, Inc
Marina Biotech, Inc
Charlestown, Massachusetts, United States
Marina Biotech is an oligonucleotide therapeutics company with the broadest drug discovery platform in the sector with the ability to develop proprietary single and double-str...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Marina Biotech, Inc

Marina Biotech, Inc
Track: A
City: Charlestown
State: Massachusetts
Country: United States
Ownership: PUBLIC
Ticker:
Stock exchange:
Schedule information will be posted soon
Marina Biotech is an oligonucleotide therapeutics company with the broadest drug discovery platform in the sector with the ability to develop proprietary single and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs, and antisense compounds. Our SMARTICLES delivery technology is in human development delivering both a single and double-stranded oligonucleotide.

Visit: http://www.marinabio.com/

Biotech Showcase™ 2015
Matinas BioPharma, Inc.
Matinas BioPharma, Inc.
Bedminster, New Jersey, United States
Matinas BioPharma is a development stage biopharmaceutical company focused on identifying and developing novel pharmaceutical products for the treatment of dyslipidemia and ca...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Matinas BioPharma, Inc.

Matinas BioPharma, Inc.
Track: A
City: Bedminster
State: New Jersey
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Matinas BioPharma is a development stage biopharmaceutical company focused on identifying and developing novel pharmaceutical products for the treatment of dyslipidemia and cardiovascular disease. The Company is developing its lead product candidate MAT9001, with the objective to establish significant differentiation as compared to existing available therapies.

Visit: http://www.matinasbiopharma.com

Biotech Showcase™ 2015
MaxCyte, Inc.
MaxCyte, Inc.
Gaithersburg, Maryland, United States
MaxCyte’s proprietary instrument/disposable system for high performance cell transfection has applications in drug discovery/development, rapid vaccine development and custo...


Share this:Email this pageShare this on LinkedInShare this on Twitter

MaxCyte, Inc.

MaxCyte, Inc.
Track: B
City: Gaithersburg
State: Maryland
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
MaxCyte’s proprietary instrument/disposable system for high performance cell transfection has applications in drug discovery/development, rapid vaccine development and customizable cell therapy commercialization. MaxCyte is a worldwide leader in large scale and clinical transfection and in engineering human cells with mRNA including its Chimeric Antigen receptor program (CAR) in T cells

Visit: http://www.maxcyte.com

Biotech Showcase™ 2015
MBio Diagnostics, Inc.
MBio Diagnostics, Inc.
Boulder, Colorado, United States
To deliver all relevant disease information in a single visit, at the clinic or in the doctor's office.


Share this:Email this pageShare this on LinkedInShare this on Twitter

MBio Diagnostics, Inc.

MBio Diagnostics, Inc.
Track: B
City: Boulder
State: Colorado
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
To deliver all relevant disease information in a single visit, at the clinic or in the doctor's office.

Visit: http://www.mbiodx.com

Biotech Showcase™ 2015
Medicenna Therapeutics, Inc
Medicenna Therapeutics, Inc
Vancouver, British Columbia, Canada
Medicenna is developing first-in-class Empowered Cytokines™ that deliver potent payloads to the tumor and its immunosuppressive microenvironment. With promising Fast Track a...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Medicenna Therapeutics, Inc

Medicenna Therapeutics, Inc
Track: B
City: Vancouver
State: British Columbia
Country: Canada
Ownership: PRIVATE
Schedule information will be posted soon
Medicenna is developing first-in-class Empowered Cytokines™ that deliver potent payloads to the tumor and its immunosuppressive microenvironment. With promising Fast Track and Orphan designated P2 clinical assets and solid IP, a Series A financing is sought to build significant value on the back of late-stage glioma trials and cancer immunotherapy partnerships.

Visit: http://www.medicenna.com

Biotech Showcase™ 2015
Medvax Technologies, Inc.
Miami, Florida, United States
Medvax is commercializing cancer vaccines, planning Ph II(b)/III trial for dentritic cell vaccine Small Cell Lung Cancer under Orphan drug approval. And planing Ph Ib/IIa tria...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Medvax Technologies, Inc.

Track: B
City: Miami
State: Florida
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Medvax is commercializing cancer vaccines, planning Ph II(b)/III trial for dentritic cell vaccine Small Cell Lung Cancer under Orphan drug approval. And planing Ph Ib/IIa trial for a Her-2 peptide cancer vaccine.

Biotech Showcase™ 2015
Memcine Pharmaceuticals, Inc.
Memcine Pharmaceuticals, Inc.
Coralville, Iowa, United States
Memcine seeks $0.5M in equity capital that will satisfy the private match requirement for a recent award of $0.5M from the Iowa Economic Development Authority.


Share this:Email this pageShare this on LinkedInShare this on Twitter

Memcine Pharmaceuticals, Inc.

Memcine Pharmaceuticals, Inc.
Track: A
City: Coralville
State: Iowa
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Memcine seeks $0.5M in equity capital that will satisfy the private match requirement for a recent award of $0.5M from the Iowa Economic Development Authority.

Visit: http://www.memcine.com/

Biotech Showcase™ 2015
Menon Biosensors, Inc.
Menon Biosensors, Inc.
San Diego, California, United States
Menon Biosensors ("Menon"), a molecular biochemistry company, applies nuclear magnetic resonance ("NMR") to directly detect molecular and immunochemistry biomarkers. The plat...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Menon Biosensors, Inc.

Menon Biosensors, Inc.
Track: A
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Menon Biosensors ("Menon"), a molecular biochemistry company, applies nuclear magnetic resonance ("NMR") to directly detect molecular and immunochemistry biomarkers. The platform represents next generation detection technology. With minimal sample preparation, sample-to-result is less than one hour. Diagnostic and detection applications are in healthcare, life sciences, and animal and food safety.

Visit: http://www.menon.us

Biotech Showcase™ 2015
Merus B.V.
Merus B.V.
Utrecht, Netherlands
Merus is a biopharmaceutical company developing bispecific antibodies, called Biclonics™, for cancer therapy. The three largest pharmaceutical companies are strategic inves...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Merus B.V.

Merus B.V.
Track: A
City: Utrecht
Country: Netherlands
Ownership: PRIVATE
Schedule information will be posted soon
Merus is a biopharmaceutical company developing bispecific antibodies, called Biclonics™, for cancer therapy. The three largest pharmaceutical companies are strategic investors in Merus : Johnson & Johnson, Novartis and Pfizer. Merus has the world-leading bispecific antibody discovery platform. This platform is being applied to build a broad, differentiated pipeline of Biclonics™ products.

Visit: http://www.merus.nl

Biotech Showcase™ 2015
MetaStat, Inc.
MetaStat, Inc.
(OTCQB:MTST)
Montclair, New Jersey, United States
MetaStat, Inc. (OTCBB: MTST) develops and commercializes best-in-class diagnostics and novel therapeutics for the early and reliable prediction and treatment of systemic metas...


Share this:Email this pageShare this on LinkedInShare this on Twitter

MetaStat, Inc.

MetaStat, Inc.
Track: D
City: Montclair
State: New Jersey
Country: United States
Ownership: PUBLIC
Ticker: MTST
Stock exchange: OTCQB
Schedule information will be posted soon
MetaStat, Inc. (OTCBB: MTST) develops and commercializes best-in-class diagnostics and novel therapeutics for the early and reliable prediction and treatment of systemic metastatic cancer. Systemic metastasis is the spread of cancer cells, through blood, from the primary tumor site to other areas of the body. MetaStat’s initial product, the MetaSite Breast™ test has been validated in two clinical studies and is slated for commercialization in 2015.

Visit: http://www.metastat.com

Biotech Showcase™ 2015
MicroBiome Therapeutics
MicroBiome Therapeutics
Broomfield, Colorado, United States
MicroBiome Therapeutics is an early-stage biotech company developing microbiome modulators for the treatment of metabolic diseases. The company's lead product, NM504, recentl...


Share this:Email this pageShare this on LinkedInShare this on Twitter

MicroBiome Therapeutics

MicroBiome Therapeutics
Track: B
City: Broomfield
State: Colorado
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
MicroBiome Therapeutics is an early-stage biotech company developing microbiome modulators for the treatment of metabolic diseases. The company's lead product, NM504, recently completed a Phase II study in prediabetes and metformin-intolerant Type 2 diabetes. In T2D patients NM504 eliminated side effects, improved dose titration, and efficacy of metformin. Additional clinical studies and partnering discussions are underway.

Visit: http://www.mbiome.com

Biotech Showcase™ 2015
Moleac
Moleac
Singapore,
Moleac is a privately held specialty bio-pharma company based in Singapore that combines a modern clinical approach along with the latest biotechnology to develop best-in-clas...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Moleac

Moleac
Track: C
City: Singapore
Ownership: PRIVATE
Schedule information will be posted soon
Moleac is a privately held specialty bio-pharma company based in Singapore that combines a modern clinical approach along with the latest biotechnology to develop best-in-class therapeutics in the areas of neurology and aging. The company’s first marketed product is NeuroAiD™ which helps patients recover faster and better from their stroke disabilities. It is registered in 25 countries.

Visit: http://www.moleac.net/main/

Biotech Showcase™ 2015
MolMed S.p.A.
MolMed S.p.A.
(Milan Stock Exchange:MLM)
Milan, Italy
MolMed is a medical biotech company, listed on the Milan Stock Exchange, focused on R&D and clinical validation of innovative therapies to treat cancer. Phase III results of d...


Share this:Email this pageShare this on LinkedInShare this on Twitter

MolMed S.p.A.

MolMed S.p.A.
Track: D
City: Milan
Country: Italy
Ownership: PUBLIC
Ticker: MLM
Stock exchange: Milan Stock Exchange
Schedule information will be posted soon
MolMed is a medical biotech company, listed on the Milan Stock Exchange, focused on R&D and clinical validation of innovative therapies to treat cancer. Phase III results of drug candidate NGR-hTNF for Malignant Pleural Mesothelioma will be available between December 2013 and January 2014. MolMed’s strategy is to out-licence NGR-hTNF.

Visit: http://www.molmed.com

Biotech Showcase™ 2015
Motif BioSciences Inc.
Motif BioSciences Inc.
New York, New York, United States
Motif has completed a robust Research Operating Plan to develop a novel antibiotic with broad spectrum gram positive efficacy, including MRSA and multi-drug resistant strains,...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Motif BioSciences Inc.

Motif BioSciences Inc.
Track: C
City: New York
State: New York
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Motif has completed a robust Research Operating Plan to develop a novel antibiotic with broad spectrum gram positive efficacy, including MRSA and multi-drug resistant strains, once daily, oral and injectable, with a low propensity for resistance. Lead series and provisional patent in 12 months, pre-clinical candidate within 18 months.

Visit: http://www.motifbio.com

Biotech Showcase™ 2015
MRI Interventions
MRI Interventions
(OTCQB:MRIC)
Memphis, Tenessee, United States
Commercial stage medical device company creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart.


Share this:Email this pageShare this on LinkedInShare this on Twitter

MRI Interventions

MRI Interventions
Track: B
City: Memphis
State: Tenessee
Country: United States
Ownership: PUBLIC
Ticker: MRIC
Stock exchange: OTCQB
Schedule information will be posted soon
Commercial stage medical device company creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart.

Visit: http://www.mriinterventions.com/

Biotech Showcase™ 2015
NANOBIOTIX
NANOBIOTIX
(Euronext:NANO)
PARIS, France
Nanobiotix (Euronext: NANO) is a nanomedicine leader. Nanobiotix pioneers novel approaches for the local treatment of cancer at much lower risk than classic drug development a...


Share this:Email this pageShare this on LinkedInShare this on Twitter

NANOBIOTIX

NANOBIOTIX
Track: D
City: PARIS
Country: France
Ownership: PUBLIC
Ticker: NANO
Stock exchange: Euronext
Schedule information will be posted soon
Nanobiotix (Euronext: NANO) is a nanomedicine leader. Nanobiotix pioneers novel approaches for the local treatment of cancer at much lower risk than classic drug development approaches. The first-in-class NanoXray technology enhances radiotherapy providing a more efficient treatment. Nanobiotix’s lead product NBTXR3 is in phase I development and partnered in Asia-Pacific.

Visit: http://www.nanobiotix.com

Biotech Showcase™ 2015
NanoViricides, Inc
NanoViricides, Inc
(NYSE MKT:NNVC)
Santa Monica, California, United States
NanoViricides has created a technology platform for the rapid creation of drugs that both target and destroy viruses. Ten different drugs have already have already been test...


Share this:Email this pageShare this on LinkedInShare this on Twitter

NanoViricides, Inc

NanoViricides, Inc
Track: D
City: Santa Monica
State: California
Country: United States
Ownership: PUBLIC
Ticker: NNVC
Stock exchange: NYSE MKT
Schedule information will be posted soon
NanoViricides has created a technology platform for the rapid creation of drugs that both target and destroy viruses. Ten different drugs have already have already been tested in over 6000 animals. These include HIV, influenza, dengue/dengue hemorrhagic fever, MERS CoV and herpes of the eyes and genitals. No toxicity has been found.  

Visit: http://www.nanoviricides.com

Biotech Showcase™ 2015
Navidea Biopharmaceuticals
Navidea Biopharmaceuticals
(NYSE MKT:NAVB)
Dublin, Ohio, United States
Navidea’s strategy is to deliver growth and shareholder return by bringing to market novel precision diagnostic radiopharmaceuticals and advancing its pipeline through acqui...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Navidea Biopharmaceuticals

Navidea Biopharmaceuticals
Track: D
City: Dublin
State: Ohio
Country: United States
Ownership: PUBLIC
Ticker: NAVB
Stock exchange: NYSE MKT
Schedule information will be posted soon
Navidea’s strategy is to deliver growth and shareholder return by bringing to market novel precision diagnostic radiopharmaceuticals and advancing its pipeline through acquisitions, partnering and commercialization. It is developing oncology and neurology products including FDA-approved Lymphoseek.

Visit: http://www.navidea.com

Biotech Showcase™ 2015
NeoGenomics, Inc.
NeoGenomics, Inc.
(NASDAQ:NEO)
Fort Myers, Florida, United States
NeoGenomics is a high-complexity CLIA–certified clinical laboratory that specializes in molecular genetics testing for cancer, the fastest growing segment of the laboratory ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

NeoGenomics, Inc.

NeoGenomics, Inc.
Track: D
City: Fort Myers
State: Florida
Country: United States
Ownership: PUBLIC
Ticker: NEO
Stock exchange: NASDAQ
Schedule information will be posted soon
NeoGenomics is a high-complexity CLIA–certified clinical laboratory that specializes in molecular genetics testing for cancer, the fastest growing segment of the laboratory industry. NeoGenomics services the needs of customers through its innovative technical-component only (“tech-only”) testing services. These services allow customers to retain the professional interpretation component of testing revenue and creates very deep and long-term customer relationships for NeoGenomics.

Visit: http://www.neogenomics.com

Biotech Showcase™ 2015
NetBio
NetBio
Waltham, Massachusetts, United States
NetBio is a commercial DNA analysis company providing a full set of technologies, products, and services used in the emerging field of Rapid DNA Analysis (RDNA). The Company i...


Share this:Email this pageShare this on LinkedInShare this on Twitter

NetBio

NetBio
Track: B
City: Waltham
State: Massachusetts
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
NetBio is a commercial DNA analysis company providing a full set of technologies, products, and services used in the emerging field of Rapid DNA Analysis (RDNA). The Company is currently commercializing its human forensic identification products to the law enforcement market through an alliance with GE Healthcare (GE). NetBio is commercializing its forensic system for use by the military and homeland security communities.

Visit: http://www.netbio.com/index.html

Biotech Showcase™ 2015
Neumedicines Inc.
Neumedicines Inc.
Pasadena, California, United States
Neumedicines is privately held company focused on the development of protein therapeutics. Lead product candidate, HemaMax(TM) for Acute Radiation Syndrome, has received $49M ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Neumedicines Inc.

Neumedicines Inc.
Track: B
City: Pasadena
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Neumedicines is privately held company focused on the development of protein therapeutics. Lead product candidate, HemaMax(TM) for Acute Radiation Syndrome, has received $49M to date in non-dilutive advanced R&D contracts from USG; stockpiling expected in 2015. Company seeks funding to support oncology clinical R&D of HemaMax(TM). Company prepared to file IND(s) and initiate phase 1/2 studies in multiple oncology indications in 2014.

Visit: http://www.neumedicines.com/

Biotech Showcase™ 2015
Neuralstem, Inc.
Neuralstem, Inc.
(NYSE MKT:CUR)
Rockville, Maryland, United States
Platform Technology • Regionally specific, fully characterized CNS human neural stem cells, cGMP mnfr. • Inventor of human neural stem cell technology is Karl Johe, Ph.D.,...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Neuralstem, Inc.

Neuralstem, Inc.
Track: D
City: Rockville
State: Maryland
Country: United States
Ownership: PUBLIC
Ticker: CUR
Stock exchange: NYSE MKT
Schedule information will be posted soon
Platform Technology • Regionally specific, fully characterized CNS human neural stem cells, cGMP mnfr. • Inventor of human neural stem cell technology is Karl Johe, Ph.D., Chairman and Chief Scientific Officer, while at NIH • First FDA-approved neural stem cell therapy trials for ALS & chronic spinal cord injury • First-in-class hippocampal neurogenic small molecule drug portfolio • 15 U.S. patents re-affirmed worldwide; 9 pending

Visit: http://neuralstem.com

Biotech Showcase™ 2015
NeuroDerm Ltd.
NeuroDerm Ltd.
Ness Ziona, Israel
NeuroDerm reformulates CNS drugs for continuous trans-dermal or sub-cutaneous administration to achieve significantly higher efficacy in major indications. ND0612 and ND0650 ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

NeuroDerm Ltd.

NeuroDerm Ltd.
Track: A
City: Ness Ziona
Country: Israel
Ownership: PRIVATE
Schedule information will be posted soon
NeuroDerm reformulates CNS drugs for continuous trans-dermal or sub-cutaneous administration to achieve significantly higher efficacy in major indications. ND0612 and ND0650 are levodopa/carbidopa formulations delivered through patch or belt pumps for Parkinson’s Disease. ND0801 is a passive, repositioned transdermal patch for cognition and attention. All are in phase 2 trials.

Visit: http://www.neuroderm.com

Biotech Showcase™ 2015
Neurotrope, Inc.
Neurotrope, Inc.
(OTCBB:NTRP)
Plantation, Florida, United States
Neurotrope, Inc. is developing two product platforms, a minimally-invasive diagnostic test for Alzheimer’s Disease and the drug candidate bryostatin for the therapeutic trea...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Neurotrope, Inc.

Neurotrope, Inc.
Track: B
City: Plantation
State: Florida
Country: United States
Ownership: PUBLIC
Ticker: NTRP
Stock exchange: OTCBB
Schedule information will be posted soon
Neurotrope, Inc. is developing two product platforms, a minimally-invasive diagnostic test for Alzheimer’s Disease and the drug candidate bryostatin for the therapeutic treatment of AD; both initiatives are currently in clinical testing phase. Neurotrope’s core technology involves activation of Protein Kinase C which has shown broad potential in treating other neurodegenerative diseases in various preclinical models which the Company is actively exploring.

Visit: http://www.neurotropebioscience.com

Biotech Showcase™ 2015
Nexvet
Nexvet
Melbourne, Victoria, Australia
Nexvet Biopharma is developing safe, more effective and specific medicines for companion animals, (cats, dogs and horses). Nexvet's portfolio focuses on inflammation, pain and...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Nexvet

Nexvet
Track: A
City: Melbourne
State: Victoria
Country: Australia
Ownership: PRIVATE
Schedule information will be posted soon
Nexvet Biopharma is developing safe, more effective and specific medicines for companion animals, (cats, dogs and horses). Nexvet's portfolio focuses on inflammation, pain and cancer. The portfolio is composed of drugs based on successful human biologics in these indications, uniquely converted to 100% species-specific versions by Nexvet’s proprietary PETisation™ technology.

Visit: http://www.nexvet.com/

Biotech Showcase™ 2015
nLife Therapeutics
nLife Therapeutics
Barcelona, Spain
nLife is developing new disease modifying treatments for CNS disorders. A neuronal specific oligonucleotide is delivered to the brain by a nose-to-brain pathway and modulates ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

nLife Therapeutics

nLife Therapeutics
Track: B
City: Barcelona
Country: Spain
Ownership: PRIVATE
Schedule information will be posted soon
nLife is developing new disease modifying treatments for CNS disorders. A neuronal specific oligonucleotide is delivered to the brain by a nose-to-brain pathway and modulates de expression of a target gene. The Parkinson's disease program is in preclinical stage with promising monkey data and the current round of financing will support the clinical development until Phase II.

Visit: http://www.n-life.es

Biotech Showcase™ 2015
Northwest Biotherapeutics
Northwest Biotherapeutics
(NASDAQ:NWBO)
Bethesda, Maryland, United States
Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side e...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Northwest Biotherapeutics

Northwest Biotherapeutics
Track: C
City: Bethesda
State: Maryland
Country: United States
Ownership: PUBLIC
Ticker: NWBO
Stock exchange: NASDAQ
Schedule information will be posted soon
Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner. The Company has a broad platform technology for DCVax dendritic cell-based vaccines.

Visit: http://www.nwbio.com

Biotech Showcase™ 2015
Novan Therapeutics
Novan Therapeutics
Durham, North Carolina, United States
Novan Therapeutics is developing nitric oxide therapies for a wide range of diseases. Novan's core technology enables the stable storage and controlled release of nitric oxid...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Novan Therapeutics

Novan Therapeutics
Track: B
City: Durham
State: North Carolina
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Novan Therapeutics is developing nitric oxide therapies for a wide range of diseases. Novan's core technology enables the stable storage and controlled release of nitric oxide. Novan has raised $20M in private investment and over $15M in grant and contract funding. Novan's initial focus is in dermatology and wound care.

Visit: http://www.novantherapeutics.com

Biotech Showcase™ 2015
NovaRx
NovaRx
San Diego, California, United States
NovaRx is a clinical stage, oncology-focused, private biopharmaceutical company. It's lead product, Lucanix®, is a therapeutic vaccine for non-small cell lung cancer, which ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

NovaRx

NovaRx
Track: A
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
NovaRx is a clinical stage, oncology-focused, private biopharmaceutical company. It's lead product, Lucanix®, is a therapeutic vaccine for non-small cell lung cancer, which has shown a survival advantage in a Phase 3 trial. The company is raising funds to launch an IPO and commence a pivotal Phase 3 trial.

Visit: http://novarx.com

Biotech Showcase™ 2015
Novogen Ltd
Novogen Ltd
(ASX:NRT)
Sydney, New South Wales, Australia
Novogen is a drug development company with joint listing on Nasdaq and ASX. One of its technology platforms is directed against aberrant stem cells, in the fields of oncology ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Novogen Ltd

Novogen Ltd
Track: C
City: Sydney
State: New South Wales
Country: Australia
Ownership: PUBLIC
Ticker: NRT
Stock exchange: ASX
Schedule information will be posted soon
Novogen is a drug development company with joint listing on Nasdaq and ASX. One of its technology platforms is directed against aberrant stem cells, in the fields of oncology and neurodegenerative disease. Its second technology platform concerns drugs targeting the cytoskeletonand intended to replace the taxane anti-cancer drugs.

Visit: http://www.novogen.com

Biotech Showcase™ 2015
Numab AG
Numab AG
Wäendswil, Switzerland
Numab AG is preclincally developing a bi-specific anti-CD3xIL5R antibody fragment to selectively eliminate eosinophil cells from the lungs of severe asthma patients upon appli...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Numab AG

Numab AG
Track: B
City: Wäendswil
Country: Switzerland
Ownership: PRIVATE
Schedule information will be posted soon
Numab AG is preclincally developing a bi-specific anti-CD3xIL5R antibody fragment to selectively eliminate eosinophil cells from the lungs of severe asthma patients upon application by inhalation. A second proprietary product targets Th17 cells to sustainably treat autoimmune diseases. Up to now the Company has been exclusively financed through collaborations.

Visit: http://www.numab.com

Biotech Showcase™ 2015
Nuron Biotech, Inc.
Nuron Biotech, Inc.
Exton, Pennsylvania, United States
Nuron Biotech markets and develops vaccines and specialty biologics for the prevention and treatment of infectious and neurodegenerative diseases. We currently market Meningi...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Nuron Biotech, Inc.

Nuron Biotech, Inc.
Track: B
City: Exton
State: Pennsylvania
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Nuron Biotech markets and develops vaccines and specialty biologics for the prevention and treatment of infectious and neurodegenerative diseases. We currently market Meningitec™ on a worldwide basis. Our lead development candidates are RELONSIV™, in Phase III development for patients with multiple sclerosis, and NU300, a Haemophilus influenzae type b conjugate vaccine (formerly marketed by Wyeth as HibTITER®).

Visit: http://www.nuronbiotech.com

Biotech Showcase™ 2015
NuvOx Pharma
NuvOx Pharma
Tucson, Arizona, United States
NuvOx Pharma is developing oxygen therapeutic to treat life threatening conditions. February 2014 will be the first clinical trial of their lead compound, NVX-108 to treat Gli...


Share this:Email this pageShare this on LinkedInShare this on Twitter

NuvOx Pharma

NuvOx Pharma
Track: B
City: Tucson
State: Arizona
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
NuvOx Pharma is developing oxygen therapeutic to treat life threatening conditions. February 2014 will be the first clinical trial of their lead compound, NVX-108 to treat Glioblastoma. In animal models they have increased effectiveness of radiation therapy and improved survival, reduced heart attack and stroke brain damage by 80%.

Visit: http://www.nuvoxpharma.com

Biotech Showcase™ 2015
Ohr Pharmaceutical Inc
Ohr Pharmaceutical Inc
(NASDAQ:OHRP)
New York, New York, United States
Ohr Pharmaceutical Inc. is a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The Comp...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Ohr Pharmaceutical Inc

Ohr Pharmaceutical Inc
Track: D
City: New York
State: New York
Country: United States
Ownership: PUBLIC
Ticker: OHRP
Stock exchange: NASDAQ
Schedule information will be posted soon
Ohr Pharmaceutical Inc. is a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The Company is focused on advancing its pipeline products currently in phase II clinical development: Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration and other ophthalmic disorders, and OHR/AVR118 for the treatment of cancer cachexia.

Visit: http://www.ohrpharmaceutical.com

Biotech Showcase™ 2015
Oligomerix, Inc.
Oligomerix, Inc.
New York, NY, New York, United States
Oligomerix is rapidly advancing small molecules and biomarkers targeting tau oligomers for Alzheimer’s disease. The lead program for inhibitors of tau oligomer formation is ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Oligomerix, Inc.

Oligomerix, Inc.
Track: B
City: New York, NY
State: New York
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Oligomerix is rapidly advancing small molecules and biomarkers targeting tau oligomers for Alzheimer’s disease. The lead program for inhibitors of tau oligomer formation is now in hit to lead optimization phase. Oligomerix, in its quest to develop disease-modifying therapeutics, is seeking strategic partners to help accelerate advancement of its programs.

Visit: http://www.oligomerix.com

Biotech Showcase™ 2015
OncoSec Medical, Inc
OncoSec Medical, Inc
(OTCQB:ONCS)
SAN DIEGO, California, United States
OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy therapy to treat solid tumors. OncoSec’s trea...


Share this:Email this pageShare this on LinkedInShare this on Twitter

OncoSec Medical, Inc

OncoSec Medical, Inc
Track: D
City: SAN DIEGO
State: California
Country: United States
Ownership: PUBLIC
Ticker: ONCS
Stock exchange: OTCQB
Schedule information will be posted soon
OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy therapy to treat solid tumors. OncoSec’s treatment aims to harness the body’s immune system to target and kill cancer cells and consists of using its proprietary electroporation platform to enhance the uptake of a locally delivered DNA-based immunocytokine.

Visit: http://WWW.ONCOSEC.COM

Biotech Showcase™ 2015
OncoTartis, Inc.
OncoTartis, Inc.
Buffalo, New York, United States
OncoTartis, Inc. is an early development stage private company with a unique approach for anti-cancer drug discovery and its first anti-leukemia (AML) product at IND preparati...


Share this:Email this pageShare this on LinkedInShare this on Twitter

OncoTartis, Inc.

OncoTartis, Inc.
Track: A
City: Buffalo
State: New York
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
OncoTartis, Inc. is an early development stage private company with a unique approach for anti-cancer drug discovery and its first anti-leukemia (AML) product at IND preparation stage. Acting through inhibiting NAMPT, this compound may have applications for other cancers as well as for a number of other diseases.

Biotech Showcase™ 2015
Opsona Therapeutics
Opsona Therapeutics
Dublin, Ireland ,
Opsona Therapeutics is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Opsona Therapeutics

Opsona Therapeutics
Track: B
City: Dublin
State: Ireland
Ownership: PRIVATE
Schedule information will be posted soon
Opsona Therapeutics is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, with specific focus on Solid Organ transplantation and Oncology.

Visit: http://www.opsona.com

Biotech Showcase™ 2015
Oragenics, Inc.
Oragenics, Inc.
(NYSE MKT:OGEN)
Tampa, Florida, United States
Oragenics is focused on becoming a leader in novel antibiotics against infectious disease and probiotics for oral health. Oragenics has established exclusive worldwide channel...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Oragenics, Inc.

Oragenics, Inc.
Track: D
City: Tampa
State: Florida
Country: United States
Ownership: PUBLIC
Ticker: OGEN
Stock exchange: NYSE MKT
Schedule information will be posted soon
Oragenics is focused on becoming a leader in novel antibiotics against infectious disease and probiotics for oral health. Oragenics has established exclusive worldwide channel collaborations for lantibiotics and probiotics, with Intrexon Corporation Inc., a leading synthetic biology company.

Visit: http://www.oragenics.com

Biotech Showcase™ 2015
Oryn Therapeutics
Oryn Therapeutics
Davis, California, United States
Oryn Therapeutics LLC is developing a proprietary cyclic peptide product for non-immunosuppressive treatment of rheumatoid arthritis and other chronic and acute inflammatory d...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Oryn Therapeutics

Oryn Therapeutics
Track: A
City: Davis
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Oryn Therapeutics LLC is developing a proprietary cyclic peptide product for non-immunosuppressive treatment of rheumatoid arthritis and other chronic and acute inflammatory disorders. Safety and efficacy has been demonstrated in multiple animal models of both acute and chronic disease.

Visit: http://www.oryntherapeutics.com

Biotech Showcase™ 2015
Oryzon
Oryzon
(Barcelona), Spain
Epigenetics is a hot spot. LSD1 inhibition is a new differentiating therapy in cancers. LSD1 selectively hits Leukemia-Stem-Cells but spares normal progenitors. It is possible...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Oryzon

Oryzon
Track: B
City: (Barcelona)
Country: Spain
Ownership: PRIVATE
Schedule information will be posted soon
Epigenetics is a hot spot. LSD1 inhibition is a new differentiating therapy in cancers. LSD1 selectively hits Leukemia-Stem-Cells but spares normal progenitors. It is possible to select genetically patients (Fast Regulatory Track). ORY-1001 is a LSD1-inhibitor in Phase I in Leukemia. Orphan Drug status by the EMA. WIth Dominant Patent Position and FTO. The First program in Clinic LSD1 in the world a. A platform with other molecules and indications. (ORY-2001 Stops Memory decay in AD)

Visit: http://www.oryzon.com

Biotech Showcase™ 2015
Oxford BioMedica plc
Oxford BioMedica plc
(LSE:OXB)
Oxford, United Kingdom
A leading clinical-stage gene-based biopharmaceutical company with six core LentiVector® platform products and four new product opportunities underway. Expertise & capabiliti...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Oxford BioMedica plc

Oxford BioMedica plc
Track: D
City: Oxford
Country: United Kingdom
Ownership: PUBLIC
Ticker: OXB
Stock exchange: LSE
Schedule information will be posted soon
A leading clinical-stage gene-based biopharmaceutical company with six core LentiVector® platform products and four new product opportunities underway. Expertise & capabilities cover the entire product lifecycle. Technology has been recognised by Sanofi, Novartis, Pfizer partners & UK Government.

Visit: http://www.oxfordbiomedica.co.uk

Biotech Showcase™ 2015
Oxygen Biotherapeutics
Oxygen Biotherapeutics
(NASDAQ:OXBT)
Morrisville, North Carolina, United States
Oxygen Biotherapeutics, Inc. is developing medical products for the acute care market. The company owns the North American rights to develop and commercialize levosimendan for...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Oxygen Biotherapeutics

Oxygen Biotherapeutics
Track: D
City: Morrisville
State: North Carolina
Country: United States
Ownership: PUBLIC
Ticker: OXBT
Stock exchange: NASDAQ
Schedule information will be posted soon
Oxygen Biotherapeutics, Inc. is developing medical products for the acute care market. The company owns the North American rights to develop and commercialize levosimendan for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome (LCOS). The company also has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte® for intravenous delivery for indications such as traumatic brain injury and stroke.

Visit: http://www.oxybiomed.com/

Biotech Showcase™ 2015
Pacific Edge Limited
Pacific Edge Limited
(NZX:PEB)
Dunedin, New Zealand
Pacific Edge is an international cancer diagnostics company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Pacific Edge Limited

Pacific Edge Limited
Track: C
City: Dunedin
Country: New Zealand
Ownership: PUBLIC
Ticker: PEB
Stock exchange: NZX
Schedule information will be posted soon
Pacific Edge is an international cancer diagnostics company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection and monitoring of cancer. Cxbladder, Pacific Edge’s leading product for the detection of bladder cancer is now commercially available, with several other products in late stage development.

Visit: http://www.pacificedge.co.nz

Biotech Showcase™ 2015
Paganini Biopharma, Inc.
Encino, California, United States
Paganini Biopharma has developed a novel monoclonal antibody that effectively targets cancer stem cells in triple negative breast cancer. A preclinical package is complete, in...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Paganini Biopharma, Inc.

Track: B
City: Encino
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Paganini Biopharma has developed a novel monoclonal antibody that effectively targets cancer stem cells in triple negative breast cancer. A preclinical package is complete, including a companion diagnostic, and the company is ready to proceed into the clinic. To date, funding has been through grants and angels.

Biotech Showcase™ 2015
PharmaCell B.V.
PharmaCell B.V.
Maastricht, Netherlands
PharmaCell is a leading Contract Manufacturing Organization for Cellular Therapies and Regenerative Medicine in Europe. We operates a state-of-the-art cGMP-Licenced facility f...


Share this:Email this pageShare this on LinkedInShare this on Twitter

PharmaCell B.V.

PharmaCell B.V.
Track: B
City: Maastricht
Country: Netherlands
Ownership: PRIVATE
Schedule information will be posted soon
PharmaCell is a leading Contract Manufacturing Organization for Cellular Therapies and Regenerative Medicine in Europe. We operates a state-of-the-art cGMP-Licenced facility for human cell & tissue culturing located centrally in Europe. PharmaCell supports Process Development, Process Optimization, Phase I to Phase III clinical trials. Next to clinical trials manufacturing, we are also equiped to support and manufacture commercial cell therapy products for the European market.

Visit: http://www.pharmacell.nl

Biotech Showcase™ 2015
PhaseRX
PhaseRX
Seattle, Washington, USA
PhaseRx is an RNA therapeutics company developing treatments for orphan liver disease using SMARTT Polymer Technology® mRNA nanoparticles -SMARTT Polymer Technology®/mRNA Th...


Share this:Email this pageShare this on LinkedInShare this on Twitter

PhaseRX

PhaseRX
Track: B
City: Seattle
State: Washington
Country: USA
Ownership: PRIVATE
Schedule information will be posted soon
PhaseRx is an RNA therapeutics company developing treatments for orphan liver disease using SMARTT Polymer Technology® mRNA nanoparticles -SMARTT Polymer Technology®/mRNA Therapeutics Express mRNA in Hepatocytes In Vivo -SMARTT Polymer Technology® is Well-Tolerated, Robust and Scalable -Polymer/mRNA nanoparticles are ideally suited for correction of single-gene defects in the liver

Visit: http://www.phaserx.com

Biotech Showcase™ 2015
PledPharma AB
PledPharma AB
(SSE:PLED)
Stockholm, Sweden
PledPharma AB is a focused Swedish pharma company with development based on the proprietary PLED-platform for protecting healthy cells against excessive oxidative stress. The ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

PledPharma AB

PledPharma AB
Track: C
City: Stockholm
Country: Sweden
Ownership: PUBLIC
Ticker: PLED
Stock exchange: SSE
Schedule information will be posted soon
PledPharma AB is a focused Swedish pharma company with development based on the proprietary PLED-platform for protecting healthy cells against excessive oxidative stress. The company has currently two programs in clinical phase II development. PLIANT in IIb within oncology and MANAMI that just completed phase IIa in acute myocardial infarction.

Visit: http://www.pledpharma.se

Biotech Showcase™ 2015
POCASTEM Co. Ltd.
POCASTEM Co. Ltd.
Seoul, Korea, South
POCASTEM develops breakthrough cardiovascular & cancer immunotherapies based on latest advances in genetic & cellular technology.  POCASTEM’s clinical pipeline includes ste...


Share this:Email this pageShare this on LinkedInShare this on Twitter

POCASTEM Co. Ltd.

POCASTEM Co. Ltd.
Track: B
City: Seoul
Country: Korea, South
Ownership: PRIVATE
Schedule information will be posted soon
POCASTEM develops breakthrough cardiovascular & cancer immunotherapies based on latest advances in genetic & cellular technology.  POCASTEM’s clinical pipeline includes stem cell therapy for cardiovascular disease, stem cell based gene therapy for cancer and B-cell vaccine immunotherapy. The company is looking for Series B Funding and additional strategic partners.

Visit: http://www.poca-stem.com/

Biotech Showcase™ 2015
Polytherics
Polytherics
London, United Kingdom
PolyTherics provides technology solutions to enable the development of better biopharmaceuticals and offers a portfolio of proprietary and complementary technologies and servi...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Polytherics

Polytherics
Track: A
City: London
Country: United Kingdom
Ownership: PRIVATE
Schedule information will be posted soon
PolyTherics provides technology solutions to enable the development of better biopharmaceuticals and offers a portfolio of proprietary and complementary technologies and services to address key needs in biopharmaceutical development. PolyTherics’ offering includes proprietary site-specific conjugation technologies for ADCs and PK/PD optimisation. In addition, through Antitope, a group company, protein immunogenicity assessment services and antibody and protein deimmunization.

Biotech Showcase™ 2015
Pono Pharma
Pono Pharma
Honolulu, Hawaii, United States
Pono Pharma is committed to the development of better treatment options for cancers and drug-resistant bacteria, with a patent-pending novel broad-spectrum antibiotic for drug...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Pono Pharma

Pono Pharma
Track: B
City: Honolulu
State: Hawaii
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Pono Pharma is committed to the development of better treatment options for cancers and drug-resistant bacteria, with a patent-pending novel broad-spectrum antibiotic for drug-resistant bacteria as well as patented proteasome inhibitors with ideal traits and promising data regarding treatment of multiple myeloma and potentially renal, ovarian, and pancreatic cancers.

Visit: http://ponocorp.com

Biotech Showcase™ 2015
Prexton Therapeutics
Geneva, Switzerland
Prexton is supported by Merck Serono Ventures with a seed investment of €2.1M. The Series A is planned for Feb/March 2014.


Share this:Email this pageShare this on LinkedInShare this on Twitter

Prexton Therapeutics

Track: B
City: Geneva
Country: Switzerland
Ownership: PRIVATE
Schedule information will be posted soon
Prexton is supported by Merck Serono Ventures with a seed investment of €2.1M. The Series A is planned for Feb/March 2014.

Visit: http://www.prextontherapeutics.com

Biotech Showcase™ 2015
PRIAXON AG
Munich, Germany
Priaxon AG, based in Munich, Germany, is a drug discovery and development company focused on developing small molecule therapeutics against hard-to-drug protein-protein intera...


Share this:Email this pageShare this on LinkedInShare this on Twitter

PRIAXON AG

Track: B
City: Munich
Country: Germany
Ownership: PRIVATE
Schedule information will be posted soon
Priaxon AG, based in Munich, Germany, is a drug discovery and development company focused on developing small molecule therapeutics against hard-to-drug protein-protein interaction targets, using a unique, proprietary technology platform PriaXplore®. Priaxon has already made two big pharma license/collaboration deals, one with Boehringer Ingelheim and one with GlaxoSmithKline, validating Priaxon’s proprietary technology platform for PPI drug discovery.

Visit: http://www.priaxon.com/content/home/index.php

Biotech Showcase™ 2015
Progenitor Cell Therapy LLC, a NeoStem, Inc. Company
Progenitor Cell Therapy LLC, a NeoStem, Inc. Company
(NASDAQ:NBS)
New York, New York, United States
NeoStem, a leader in the emerging cellular therapy industry, is developing novel proprietary cell therapy products and operating a revenue-generating contract development and ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Progenitor Cell Therapy LLC, a NeoStem, Inc. Company

Progenitor Cell Therapy LLC, a NeoStem, Inc. Company
Track: C
City: New York
State: New York
Country: United States
Ownership: PUBLIC
Ticker: NBS
Stock exchange: NASDAQ
Schedule information will be posted soon
NeoStem, a leader in the emerging cellular therapy industry, is developing novel proprietary cell therapy products and operating a revenue-generating contract development and manufacturing organization that provides services to the industry. This unique combination provides NeoStem with cost effective in-house product development capabilities and immediate revenue and cash flow generation.

Visit: http://www.neostem.com

Biotech Showcase™ 2015
ProMetic
ProMetic
(TSE:PLI)
Laval, Quebec, Canada
ProMetic has globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development targeting fibrosis, anemia, autoimmune diseases/i...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ProMetic

ProMetic
Track: C
City: Laval
State: Quebec
Country: Canada
Ownership: PUBLIC
Ticker: PLI
Stock exchange: TSE
Schedule information will be posted soon
ProMetic has globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development targeting fibrosis, anemia, autoimmune diseases/inflammation and certain nephropathies .  ProMetic offers its technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens and uses its own affinity technology to develop best-in-class therapeutics.

Visit: http://www.prometic.com

Biotech Showcase™ 2015
Prophylix Pharma Inc.
Prophylix Pharma Inc.
New York, New York, United States
Prophylix Pharma develops an orphan, first-in-class prophylaxis for the prevention of excessive bleeding in fetuses and newborns due to fetal neonatal alloimmune thrombocytope...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Prophylix Pharma Inc.

Prophylix Pharma Inc.
Track: A
City: New York
State: New York
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Prophylix Pharma develops an orphan, first-in-class prophylaxis for the prevention of excessive bleeding in fetuses and newborns due to fetal neonatal alloimmune thrombocytopenia (FNAIT). Today, such bleeding causes 1,000 cases of life-long disability or death.The plasma-derived prophylaxis is very similar to anti-D, safe and low-risk.

Visit: http://www.prophylixpharma.com

Biotech Showcase™ 2015
Protagonist Therapeutics
Protagonist Therapeutics
Milpitas, California, United States
Protagonist is discovering and developing ‘Orally Stable Peptides’ based NCEs against validated inflammatory targets and GI diseases, and expects its first IND candidate n...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Protagonist Therapeutics

Protagonist Therapeutics
Track: B
City: Milpitas
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Protagonist is discovering and developing ‘Orally Stable Peptides’ based NCEs against validated inflammatory targets and GI diseases, and expects its first IND candidate nomination in 2014. Protagonist raised $ 18 M in 2013 to expand its proprietary technology platform and generate oral NCEs against clinical targets validated through injectable antibodies.

Visit: http://www.protagonist-inc.com

Biotech Showcase™ 2015
Protea Biosciences
Protea Biosciences
Morgantown, West Virginia, United States
Protea is a biomolecular information company, whose proprietary technology enables Direct Biomolecular Imaging – the ability to identify and display biomolecules in tissue a...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Protea Biosciences

Protea Biosciences
Track: A
City: Morgantown
State: West Virginia
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Protea is a biomolecular information company, whose proprietary technology enables Direct Biomolecular Imaging – the ability to identify and display biomolecules in tissue and cells, without touching or pretreating samples. Protea delivers robust biomolecular information to customers focused on drug and life science research, and biomarker discovery.

Visit: http://www.proteabio.com

Biotech Showcase™ 2015
Pulmokine Inc.
Pulmokine Inc.
Rensselaer, New York, United States
Pulmokine Inc. is developing a novel inhaled PDGF receptor inhibitor for the treatment of Pulmonary Arterial Hypertension.  The company’s lead candidate is more potent and ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Pulmokine Inc.

Pulmokine Inc.
Track: A
City: Rensselaer
State: New York
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Pulmokine Inc. is developing a novel inhaled PDGF receptor inhibitor for the treatment of Pulmonary Arterial Hypertension.  The company’s lead candidate is more potent and selective than imatinib. The company has raised over $3M USD from the NHLBI to carry its program through IND enabling studies.

Visit: http://www.pulmokine.net

Biotech Showcase™ 2015
PurGenesis
PurGenesis
Canada
PurGenesis Technologies, a Canadian private botanical pharmaceutical company with proprietary extraction technology, has developed 3 patented natural pharmaceuticals in phase ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

PurGenesis

PurGenesis
Track: D
Country: Canada
Ownership: PRIVATE
Schedule information will be posted soon
PurGenesis Technologies, a Canadian private botanical pharmaceutical company with proprietary extraction technology, has developed 3 patented natural pharmaceuticals in phase 2: Ulcerative Colitis, Psoriasis and Atopic Dermatitis; and 3 anti-aging cosmeceuticals, formulated from the thylakoids of organic baby spinach. In vitro and in vivo experiments demonstrate potent anti-inflammatory, immunomodulatory and anti-oxidant activity.

Biotech Showcase™ 2015
Q Therapeutics
Q Therapeutics
(:Non-Trading)
Salt Lake City, Utah, United States
Q Therapeutics is developing adult stem cell therapies to treat debilitating diseases of the central nervous system (CNS).  The Company's first product, Q-Cells®, is a cell-...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Q Therapeutics

Q Therapeutics
Track: C
City: Salt Lake City
State: Utah
Country: United States
Ownership: PUBLIC
Ticker: Non-Trading
Stock exchange:
Schedule information will be posted soon
Q Therapeutics is developing adult stem cell therapies to treat debilitating diseases of the central nervous system (CNS).  The Company's first product, Q-Cells®, is a cell-based therapeutic intended to restore or preserve normal activity of neurons.  Q's initial clinical target is ALS, with a first IND submission expected in 2014.

Visit: http://www.qthera.com

Biotech Showcase™ 2015
Rebiotix Inc
Rebiotix Inc
Roseville, Minnesota, United States
Rebiotix is a biotechnology company founded to revolutionize the treatment of challenging gastrointestinal diseases by harnessing the power of the microbiome. We have develop...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Rebiotix Inc

Rebiotix Inc
Track: A
City: Roseville
State: Minnesota
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Rebiotix is a biotechnology company founded to revolutionize the treatment of challenging gastrointestinal diseases by harnessing the power of the microbiome. We have developed a unique drug platform technology that uses live human-derived microbes to treat disease. The first target is recurrent Clostridium difficile (C diff) disease, a life-threatening infection.

Visit: http://www.rebiotix.com/

Biotech Showcase™ 2015
Relburn-Metabolomics
Relburn-Metabolomics
Westfield, New Jersey, United States
Relburn-Metabolomics is developing new treatments for gout.  Clinically validated in > 300 patients, our drugs are potent bifunctional inhibitors of both xanthine oxidase and...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Relburn-Metabolomics

Relburn-Metabolomics
Track: B
City: Westfield
State: New Jersey
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Relburn-Metabolomics is developing new treatments for gout.  Clinically validated in > 300 patients, our drugs are potent bifunctional inhibitors of both xanthine oxidase and URAT1.  Relburn is conducting preclinical IND-enabling work for a Phase 1 trial of an optimized lead compound. The Company is currently seeking Seed financing to advance our clinical programs.

Visit: http://www.relburn.com

Biotech Showcase™ 2015
Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc.
New York, New York, United States
Relmada Therapeutics, Inc. is a clinical stage, private biopharmaceutical company with a diversified portfolio of four products and a deep early stage pipeline for the treatme...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.
Track: A
City: New York
State: New York
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Relmada Therapeutics, Inc. is a clinical stage, private biopharmaceutical company with a diversified portfolio of four products and a deep early stage pipeline for the treatment of pain.  Relmada’s strategy focuses on two complementary pillars: the improvement of proven drug candidates with novel delivery methods and pharmaceutical compositions and the development of d-methadone as an innovative NMDA (N-Methyl-D-aspartate) inhibitor platform. 

Visit: http://www.relmada.com

Biotech Showcase™ 2015
ReNeuron Group plc
ReNeuron Group plc
(LSE:RENE.L)
Guildford, United Kingdom
ReNeuron is a leading, clinical-stage stem cell therapy development business.  ReNeuron’s primary therapeutic targets are stroke, critical limb ischaemia and retinitis pigm...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ReNeuron Group plc

ReNeuron Group plc
Track: C
City: Guildford
Country: United Kingdom
Ownership: PUBLIC
Ticker: RENE.L
Stock exchange: LSE
Schedule information will be posted soon
ReNeuron is a leading, clinical-stage stem cell therapy development business.  ReNeuron’s primary therapeutic targets are stroke, critical limb ischaemia and retinitis pigmentosa. The Company recently completed a $50m raise to fully fund its clinical development programmes to key milestones over the next three years. Key investors include Invesco and Abingworth.

Visit: http://www.reneuron.com

Biotech Showcase™ 2015
RepliCel Life Sciences
RepliCel Life Sciences
(OTCQB:REPCF)
Vancouver, British Columbia, Canada
RepliCel is focused on cellular deficits in certain chronic conditions using autologous therapies derived from hair follicle cells. Disclosed indications include chronic tendi...


Share this:Email this pageShare this on LinkedInShare this on Twitter

RepliCel Life Sciences

RepliCel Life Sciences
Track: C
City: Vancouver
State: British Columbia
Country: Canada
Ownership: PUBLIC
Ticker: REPCF
Stock exchange: OTCQB
Schedule information will be posted soon
RepliCel is focused on cellular deficits in certain chronic conditions using autologous therapies derived from hair follicle cells. Disclosed indications include chronic tendinosis (fibroblasts) and pattern baldness (dermal sheath cup cells). Shiseido has licensed RCH-01 for a geographic territory. P2 clinical trials for both therapies will begin in 2014.

Visit: http://www.replicel.com

Biotech Showcase™ 2015
Resverlogix Corp.
Resverlogix Corp.
(TSX:RVX)
Calgary, Alberta, Canada
Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company developing compounds involving ApoA-I production. RVX-208 is a first-in-class small molecule in developme...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Resverlogix Corp.

Resverlogix Corp.
Track: D
City: Calgary
State: Alberta
Country: Canada
Ownership: PUBLIC
Ticker: RVX
Stock exchange: TSX
Schedule information will be posted soon
Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company developing compounds involving ApoA-I production. RVX-208 is a first-in-class small molecule in development for the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer’s disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials.

Visit: http://www.resverlogix.com/

Biotech Showcase™ 2015
Reviva Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
San Jose, California, United States
Reviva Pharmaceuticals Inc (Reviva) is a privately held fast growing clinical stage pharmaceutical company focused on the development and commercialization of new, safe and hi...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Reviva Pharmaceuticals Inc

Reviva Pharmaceuticals Inc
Track: A
City: San Jose
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Reviva Pharmaceuticals Inc (Reviva) is a privately held fast growing clinical stage pharmaceutical company focused on the development and commercialization of new, safe and highly effective therapies for central nervous system (CNS), metabolic, cardiovascular and inflammatory diseases. Reviva is developing a portfolio of internally discovered innovative therapies using chemical genomics driven approches that hold key to improved patient compliance.

Visit: http://www.revivapharma.com

Biotech Showcase™ 2015
Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc.
(NYSE:RNN)
Rockville, Maryland, United States
Rexahn Pharmaceuticals is a targeted oncology company, with an early stage pipeline. Data from an ongoing Phase I study of their p68 RNA helicase inhibitor (RX-5902) is expect...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals, Inc.
Track: C
City: Rockville
State: Maryland
Country: United States
Ownership: PUBLIC
Ticker: RNN
Stock exchange: NYSE
Schedule information will be posted soon
Rexahn Pharmaceuticals is a targeted oncology company, with an early stage pipeline. Data from an ongoing Phase I study of their p68 RNA helicase inhibitor (RX-5902) is expected 1H '14, and the Company plans to initiate two more studies by the end of 2013: Phase IIa study of Archexin, an Akt1 inhibitor in Renal Cell Carcinoma, and a Phase I study of a DNA synthesis inhibitor, RX-3117, in solid tumors.

Visit: http://www.rexahn.com/cms/

Biotech Showcase™ 2015
RhinoCyte Inc.
RhinoCyte Inc.
Louisville, Kentucky, United States
RhinoCyte™, Inc. is a biopharmaceutical company seeking to change the way neurodegenerative diseases are treated. By leveraging our transformational technology, we have demo...


Share this:Email this pageShare this on LinkedInShare this on Twitter

RhinoCyte Inc.

RhinoCyte Inc.
Track: B
City: Louisville
State: Kentucky
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
RhinoCyte™, Inc. is a biopharmaceutical company seeking to change the way neurodegenerative diseases are treated. By leveraging our transformational technology, we have demonstrated the potential to shift the treatment paradigm and significantly improve patients’ lives.

Visit: http://rhinocyte.com/site/

Biotech Showcase™ 2015
RiboMed
RiboMed
Carlsbad, California, United States
RiboMed provides DNA methylation analysis with 100-fold greater sensitivity than competing methods using its proprietary detection technology, Abscription®. Epigenetic diagn...


Share this:Email this pageShare this on LinkedInShare this on Twitter

RiboMed

RiboMed
Track: A
City: Carlsbad
State: California
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
RiboMed provides DNA methylation analysis with 100-fold greater sensitivity than competing methods using its proprietary detection technology, Abscription®. Epigenetic diagnostic and RUO products, CRO services, and technology/test out-licensing are available. GliomaSTRAT™, a brain cancer prognostic/theranostic LDT, is offered through its CLIA/CAP Clinical Services Lab. Seeking first institutional funding, Series B.

Visit: http://www.ribomed.com

Biotech Showcase™ 2015
RXi Pharmaceuticals, Corp.
RXi Pharmaceuticals, Corp.
(OTCQB:RXII)
Westborough, Massachusetts, United States
RXi Pharmaceuticals Corporation is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generatio...


Share this:Email this pageShare this on LinkedInShare this on Twitter

RXi Pharmaceuticals, Corp.

RXi Pharmaceuticals, Corp.
Track: D
City: Westborough
State: Massachusetts
Country: United States
Ownership: PUBLIC
Ticker: RXII
Stock exchange: OTCQB
Schedule information will be posted soon
RXi Pharmaceuticals Corporation is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform. RXi’s first RNAi product candidate, RXI-109, entered into RXi’s first human clinical trial in 2012. RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.

Visit: http://www.rxipharma.com

Biotech Showcase™ 2015
Savara
Savara
Austin, Texas, United States
Savara Pharmaceuticals is a specialty pharmaceutical company developing AeroVanc - the first dry powder inhaled antibiotic for the treatment of methicillin-resistant Staphyloc...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Savara

Savara
Track: A
City: Austin
State: Texas
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Savara Pharmaceuticals is a specialty pharmaceutical company developing AeroVanc - the first dry powder inhaled antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis.

Visit: http://www.savarapharma.com

Biotech Showcase™ 2015
SCIderm GmbH
SCIderm GmbH
Hamburg, Germany
Target audience: - Institutional investors - Research focused life science companies (Start-ups, Biotech, Pharma) Key topics of the talk: a.) Introduction of PARTUM Consult - ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

SCIderm GmbH

SCIderm GmbH
Track: A
City: Hamburg
Country: Germany
Ownership: PRIVATE
Schedule information will be posted soon
Target audience: - Institutional investors - Research focused life science companies (Start-ups, Biotech, Pharma) Key topics of the talk: a.) Introduction of PARTUM Consult - Lifescience Investment Partners: acceleration for idea scouting, drug development & preclinical stages by an expert group of medical, regulatory & commercial advisors; b.) SCIderm - unsurpassed in dermatological research: smooth execution of clinical phase 1 - 4 programs by contracting a specialized research organization;

Visit: http://www.sciderm.com

Biotech Showcase™ 2015
Senesco Technologies, Inc
Senesco Technologies, Inc
(OTCQB:SNTI)
Bridgewater, New Jersey, United States
Senesco Technologies is a clinical-stage biotech company specializing in cancer therapeutics. Its proprietary gene regulation technology has demonstrated the ability to kill c...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Senesco Technologies, Inc

Senesco Technologies, Inc
Track: D
City: Bridgewater
State: New Jersey
Country: United States
Ownership: PUBLIC
Ticker: SNTI
Stock exchange: OTCQB
Schedule information will be posted soon
Senesco Technologies is a clinical-stage biotech company specializing in cancer therapeutics. Its proprietary gene regulation technology has demonstrated the ability to kill cancer cells and protect healthy cells from premature death. The Company is currently in a Phase 1b/2a trial with a product candidate that is designed to treat B-cell cancers.

Visit: http://www.senesco.com

Biotech Showcase™ 2015
Sensorion
Sensorion
Montpellier, France
Sensorion is a specialty pharma dedicated to new drug development for the treatment of inner ear disorders (vertigo, hearing loss, tinnitus), an untapped market with significa...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Sensorion

Sensorion
Track: B
City: Montpellier
Country: France
Ownership: PRIVATE
Schedule information will be posted soon
Sensorion is a specialty pharma dedicated to new drug development for the treatment of inner ear disorders (vertigo, hearing loss, tinnitus), an untapped market with significant unmet needs. The company has 3 distinct small molecule programs in late preclinical phase and aims to enter into human testing in 2014. The company, private and VC backed, has raised €4m dilutive financing to date and received non-dilutive grants.

Visit: http://www.sensorion-pharma.com/

Biotech Showcase™ 2015
Senz Oncology Pty Ltd
Senz Oncology Pty Ltd
Eltham, Victoria, Australia
Senz Oncology leverages the Australian regulatory and taxation environment to conduct time- and cost-effective clinical studies under licensing, co-development or fee-for-serv...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Senz Oncology Pty Ltd

Senz Oncology Pty Ltd
Track: B
City: Eltham
State: Victoria
Country: Australia
Ownership: PRIVATE
Schedule information will be posted soon
Senz Oncology leverages the Australian regulatory and taxation environment to conduct time- and cost-effective clinical studies under licensing, co-development or fee-for-service arrangements. Its lead program is VAL-1000, a small molecule in Phase I/II for acute leukemias. Senz has a second unfunded program and looks to meet potential investors or partners.

Visit: http://www.senzoncology.com/

Biotech Showcase™ 2015
Sernova Corp
Sernova Corp
(TSX-V:SVA)
London, Ontario, Canada
Sernova Corp. is a Clinical Stage company commercializing regenerative medicine products for chronic metabolic, neurological, and haematological diseases with first product fo...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Sernova Corp

Sernova Corp
Track: D
City: London
State: Ontario
Country: Canada
Ownership: PUBLIC
Ticker: SVA
Stock exchange: TSX-V
Schedule information will be posted soon
Sernova Corp. is a Clinical Stage company commercializing regenerative medicine products for chronic metabolic, neurological, and haematological diseases with first product focus on diabetes and haemophilia. Sernova's platform technologies include the Cell Pouch System(TM) an implantable medical device for therapeutic cells, therapeutic cells and Sertolin(TM) which provides local immune protection.

Visit: http://www.sernova.com

Biotech Showcase™ 2015
Shenogen Pharma Group
Shenogen Pharma Group
Beijing, Beijing, China
Shenogen is targeting ER-alpha36, a novel surface estrogen receptor to develop anti-cancer therapy.  Its lead compound icaritn which targets ER-alpha36 and other cancer stem ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Shenogen Pharma Group

Shenogen Pharma Group
Track: B
City: Beijing
State: Beijing
Country: China
Ownership: PRIVATE
Schedule information will be posted soon
Shenogen is targeting ER-alpha36, a novel surface estrogen receptor to develop anti-cancer therapy.  Its lead compound icaritn which targets ER-alpha36 and other cancer stem cell targets is in Ph II trial in advanced HCC patients. A follow-up compound SG1153 is ready for IND-enabling study also for treating multiple cancers. The company is also developing ADC molecule treating cancer patients with high expression of ER-alpha36.

Visit: http://www.shenogen.com.cn/

Biotech Showcase™ 2015
Shield Therapeutics
Shield Therapeutics
Newcastle, United Kingdom
Shield Therapeutics is an independent speciality pharmaceutical company focused on targeted development and commercialisation of novel small-mineral medicines addressing clear...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Shield Therapeutics

Shield Therapeutics
Track: B
City: Newcastle
Country: United Kingdom
Ownership: PRIVATE
Schedule information will be posted soon
Shield Therapeutics is an independent speciality pharmaceutical company focused on targeted development and commercialisation of novel small-mineral medicines addressing clear unmet medical needs. Its near-term focus is on approval and commercialisation of ST10, a novel oral ferric iron-based therapy in Phase 3 development, which addresses the substantial iron deficiency anaemia market.

Visit: http://www.shieldtherapeutics.com/

Biotech Showcase™ 2015
Simcere Pharmaceutical Group.
Simcere Pharmaceutical Group.
Nanjing,, Jiangsu, China
Simcere(SCR) is a leading innovative pharmaceutical company in China and its current portfolio is comprised of first-to-market generics and innovative pharmaceuticals, includi...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Simcere Pharmaceutical Group.

Simcere Pharmaceutical Group.
Track: A
City: Nanjing,
State: Jiangsu
Country: China
Ownership: PRIVATE
Schedule information will be posted soon
Simcere(SCR) is a leading innovative pharmaceutical company in China and its current portfolio is comprised of first-to-market generics and innovative pharmaceuticals, including biologics. Simcere recently launched BioSciKin PharmaPioneers, an independent incubator and investment program, to partner with biotech companies to develop IND-ready and early-stage innovative clinical assets in China.

Visit: http://www.simcere.com

Biotech Showcase™ 2015
Skyepharma AG
Skyepharma AG
(LSE:SKP)
Muttenz, Switzerland
Skyepharma is a specialty drug delivery company applying its proven scientific expertise and proprietary technologies to develop oral and inhalation products. In a proof of co...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Skyepharma AG

Skyepharma AG
Track: D
City: Muttenz
Country: Switzerland
Ownership: PUBLIC
Ticker: SKP
Stock exchange: LSE
Schedule information will be posted soon
Skyepharma is a specialty drug delivery company applying its proven scientific expertise and proprietary technologies to develop oral and inhalation products. In a proof of concept study Skyepharma’s most recent development SKP-1052 showed efficacy in the reduction of nocturnal hypoglycemia in diabetes patients.

Visit: http://www.skyepharma.com

Biotech Showcase™ 2015
Soligenix, Inc.
Soligenix, Inc.
(OTCQB:SNGX)
Princeton, New Jersey, United States
Soligenix is a clinical stage company targeting treatments for inflammatory orphan diseases and areas of unmet medical need such as, oral mucositis, pediatric Crohn’s diseas...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Soligenix, Inc.

Soligenix, Inc.
Track: D
City: Princeton
State: New Jersey
Country: United States
Ownership: PUBLIC
Ticker: SNGX
Stock exchange: OTCQB
Schedule information will be posted soon
Soligenix is a clinical stage company targeting treatments for inflammatory orphan diseases and areas of unmet medical need such as, oral mucositis, pediatric Crohn’s disease and chronic GVHD. It is also developing heat stable biodefense vaccines and therapeutics with government funding up to $34M, and through collaboration with Intrexon Corporation.

Visit: http://www.soligenix.com

Biotech Showcase™ 2015
Sorrento Therapeutics
Sorrento Therapeutics
(NASDAQ:SRNE)
San Diego, California, United States
Sorrento Therapeutics is a development-stage company focused on cancer management. Sorrento is advancing Cynviloq, a next-generation paclitaxel formulation via 505(b)(2) pathw...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Sorrento Therapeutics

Sorrento Therapeutics
Track: D
City: San Diego
State: California
Country: United States
Ownership: PUBLIC
Ticker: SRNE
Stock exchange: NASDAQ
Schedule information will be posted soon
Sorrento Therapeutics is a development-stage company focused on cancer management. Sorrento is advancing Cynviloq, a next-generation paclitaxel formulation via 505(b)(2) pathway. Sorrento is also clinically developing a non-opiate TRPV1 agonist, Resiniferatoxin, for cancer patients with intractable pain. Sorrento’s assets further include a diverse human antibody library and proprietary ADC platform.

Visit: http://www.sorrentotherapeutics.com

Biotech Showcase™ 2015
Spring Bank Pharmaceuticals, Inc.
Spring Bank Pharmaceuticals, Inc.
Spring Bank is engaged in the discovery and development of novel therapeutics based on its “Small Molecule Nucleic Acid” (SMNH) chemistry platform. Its most advanced candi...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals, Inc.
Track: A
Ownership: PRIVATE
Schedule information will be posted soon
Spring Bank is engaged in the discovery and development of novel therapeutics based on its “Small Molecule Nucleic Acid” (SMNH) chemistry platform. Its most advanced candidate, SB 9200 for the treatment of HBV and HCV, is in Ph. 1 clinical studies. Spring Bank also has preclinical programs in anti-virals and inflammation.

Visit: http://springbankpharm.com/

Biotech Showcase™ 2015
Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc.
(OTCQB:SBOTF)
Port Hueneme, California, United States
Stellar Biotechnologies is targeting the immunotherapy arena with its world-leading KLH technology.  KLH is an important immune-stimulating molecule widely used in therapeuti...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc.
Track: D
City: Port Hueneme
State: California
Country: United States
Ownership: PUBLIC
Ticker: SBOTF
Stock exchange: OTCQB
Schedule information will be posted soon
Stellar Biotechnologies is targeting the immunotherapy arena with its world-leading KLH technology.  KLH is an important immune-stimulating molecule widely used in therapeutic vaccines (active immunotherapies) and as a finished product to measure immune status.  Stellar develops and improves KLH-based immunotherapies and is the only company with sustainable KLH manufacturing capabilities.

Visit: http://www.stellarbiotech.com

Biotech Showcase™ 2015
Stevia First
Stevia First
(OTCBB:STVF)
Yuba City, California, United States
Stevia First Corp. is seeking to establish a vertically-integrated enterprise in the U.S. that uses technological expertise in fermentation-based stevia production and improve...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Stevia First

Stevia First
Track: C
City: Yuba City
State: California
Country: United States
Ownership: PUBLIC
Ticker: STVF
Stock exchange: OTCBB
Schedule information will be posted soon
Stevia First Corp. is seeking to establish a vertically-integrated enterprise in the U.S. that uses technological expertise in fermentation-based stevia production and improves upon traditional stevia farming and processing methods. Stevia First's U.S. operations are located in the heart of California's Central Valley, one of the world's most productive agricultural regions.

Visit: http://www.steviafirst.com

Biotech Showcase™ 2015
SUSAVION
SUSAVION
TEMPE, Arizona, United States
Susavion Biosciences, has a platform to identify novel peptidic drugs that trigger activation of several types of immune effector cells with a focus on cancer. Compounds have ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

SUSAVION

SUSAVION
Track: B
City: TEMPE
State: Arizona
Country: United States
Ownership: PRIVATE
Schedule information will be posted soon
Susavion Biosciences, has a platform to identify novel peptidic drugs that trigger activation of several types of immune effector cells with a focus on cancer. Compounds have been shown in vivo to stimulate the activation of CD8 T cells and maturation of macrophages, dendritic cells and NK cells.

Visit: http://www.susavion.com

Biotech Showcase™ 2015